INDEX TO VOLUME 13

AUTHOR INDEX

A

AARONS, R. *see* MOLINOFF, P.B., 365S

ADELUSI, S.A. & SALAKO, L.A. Protein binding of chloroquine in the presence of aspirin, 451

ADJEPON-YAMOAH, K.K., EDWARDS, G., BRECKENRIDGE, A.M., ORME, M.L.E. & WARD, S.A. Effect of renal disease on pharmacokinetics of diethylcarbamazine in man, 829

AELLIG, W.H. Pindolol—a β-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations, 187S

AELLIG, W.H. Clinical pharmacological experiments with bopindolol (LT31-200): a long acting β-adrenoceptor blocking drug with partial agonist activity, 267P

AELLIG, W.H. *see* SCHLÜTER, K.J., 407S

AGABITI-ROSEI, E., ALICANDRI, C.L. BESCHI, M., CASTELLANO, M., FARIELLO, R., MONTINI, E., MUIESAN, M.L., ROMANELLI, G. & MUIESAN, G. Acute and chronic hypotensive effect of labetalol and relationship with pretreatment plasma noradrenaline levels, 87S

AGABITI-ROSEI, E. *see* SONKODI, S., 341

AHMAD, R.A. *see* VANDENBURG, M.J., 747

AHUJA, R., SILKE, B., NELSON, G.I.C. & TAYLOR, S.H. Interaction between incremental doses of a calcium antagonist and the pressor response to common stimuli in hypertension, 610P

AL-AZAWI, S. *see* HUGHES, R., 355

ALDEN, J. *see* HUNT, P.S., 233

ALICANDRI, C.L. *see* AGABITI-ROSEI, E., 87S

ALLEN, M.C. *see* BULLINGHAM, R.E.S., 665

ALPERS, J.H. *see* RUFFIN, R.E., 325S

AMBROSIONI, E. *see* MALINI, P.L., 123S

ANDERSON, A.E. *see* McNEIL, J.J., 75S

ANDREASEN, F., CHRISTENSEN, C.K., JAKOBSEN, F.K., JANSEN, J., MOGENSEN, C.E. & PEDERSEN, O.L. The individual variation in pharmacokinetics and pharmacodynamics of frusemide in young, normal, male subjects, 272P

ANTOON, A. *see* FAGARD, R., 13S

APOIL, E. *see* VALETTE, H., 250

ARNDTS, D. *see* HARRON, D.W.G., 821

ARONSON, J.K. *see* PUGH, S.E., 271P

ARONSON, J.K. *see* KHAN, A.K.A., 523

ARONSON, J.K., GRAHAME-SMITH, D.G., HALLIS, K.F. & WHITE, N.J. The effect of digoxin on the *in vivo* disposition of an oral load of rubidium chloride, 606P

ARNOLD, J.M.O. & McDEVITT, D.G. Heart rate and blood pressure responses to intravenous boluses of isoprenaline before and after atropine, 266P

ARNOLD, J.M.O. & McDEVITT, D.G. Interpretation of isoprenaline dose-response curves in the presence of selective and non-selective β-adrenoceptor blocking drugs, 585P

ARUNKUMAR SHASTRI, R. Plasma protein binding and half-life of sulphisoxazole, 249

ASBURY, M.J. *see* McINNES, G.T., 331

ATKINSON, A.B., CUMMING, A.M.M., BROWN, J.J., FRASER, R., LECKIE, B., LEVER, A.F., MORTON, J.J. & ROBERTSON, J.I.S. Captopril treatment: interdose variations in renin, antiogensins I and II, aldosterone and blood pressure, 85S

AUKLAND, A. *see* HURLOW, R.A., 803

AXELSON, J.E. *see* ELVIN, A.T., 872

B

BACK, D.J., BRECKENRIDGE, A.M., MacIVER, M., ORME, M., PURBA, H.S., ROWE, P.H. & TAYLOR, I. The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradial in humans, 325

BACK, D.J., BRECKENRIDGE, A.M., MacIVER, M., ORME, M., STAIGER, C., THOMAS, E. & TJIA, J. The interaction between ampicillin and oral contraceptive steroids in women, 280P

BAILEY, R.R. *see* WOOD, A.J., 81S

BAIR, I.A. *see* BEEVER, I.W., 599P

BALALI-MOOD, M. *see* CRITCHLEY, J.A.J.H., 276P

BALANT, L. *see* DAYER, P., 750

BANKS, R.A. *see* MacGREGOR, G.A., 859

BARBER, H.E. *see* STEELE, W.H., 595P

BARCHOWSKY, A., SHAND, D.G., STARGEL, W.W., WAGNER, G.S. & ROUTLEDGE, P.A. On the role of α_1-acid glycoprotein in lignocaine accumulation following myocardial infarction, 411

BARNETT, D.B., COOK, N., DICKINSON, K.E.J. & NAHORSKI, S.R. Radio-receptor assay for β-adrenoceptor antagonists using solubilized receptor protein, 284P

BARNETT, D.B., HELLER, K.B. & JAGGER, C. Comparison of β-adrenoceptor blocking activity measured by radioreceptor assay and physiological cardiac β-adrenoceptor blockade, 613P

BASHIR, A., LEWIS, M.J. & HENDERSON, A.H. Pharmacokinetics of organic nitrate preparations, 287P

BASRAN, G.S. & PAUL, W. The effects of adrenoceptor agonists and antagonists on a mediator induced wheal response in human skin, 607P

BATEMAN, D.N., GOOPTU, D. & WHITTINGHAM, T.A. Effects of domperidone on gastric emptying of liquid in man, 675

BAXTER, R., HOLT, D.W. & JAMIESON, R. Plasma concentrations of tocainide using an intravenous and oral dosage schedule for prophylaxis following myocardial infarction, 591P

BEATTIE, J.M. *see* TWEDDEL, A.C., 256

BEEVER, I.W., BAIR, I.A. & BRODIE, M.J. Circulating hydrazine during treatment with isoniazid and rifampicin in man, 599P
BEHRENBECK, D.W. *see* HOMBACH, V., 285S
BEILIN, L.J. Is hypertensive vascular disease reversible, 117
BELL, G.D., CLEGG, R.J., ELLIS, W.R., MIDDLETON, B., SOMERVILLE, K. & WHITE, D.A. How does Rowachol, a mixture of plant monoterpenes, enhance the cholelitholytic potential of low and medium dose chenodeoxycholic acid, 278P
BENDER, F. *see* BRISSE, B., 421S
BENFIELD, G.F.A. & HUNTER, K.R. Oxprenolol, methyldopa and lipids in diabetes mellitus, 219
BENJAMIN, I.S. *see* BRODIE, M.J., 277P
BENNETT, P.N., JOHN, V.A. & WHITMARSH, V.B. Effect of rifampicin on metoprolol and antipyrine kinetics, 387
BERDEAUX, A. & GIUDICELLI, J.F. Intrinsic sympathomimetic activity and coronary blood flow, 175S
BERGAN, T. *see* JOSEFSSON, K., 685
BERLIN, E. *see* THULESIUS, O., 229S
BERRY, D. *see* GIBBERD, F.B., 455
BERTACCINI, G. *see* SCARPIGNATO, C., 252
BERTHOLET, A. *see* CLARK, B.J., 149S
BERTINIERI, G. *see* MANCIA, G., 27S
BERTLER, A. *see* LARSSON, R., 163
BESOHI, M. *see* AGABITI-ROSEI, E., 87S
BEVERIDGE, T. *see* HITZENBERGER, G., 217S
BEYER, K.H. Chlorothiazide, 15
BHATTACHARJEE, P. *see* WALDEN, R.J., 359S
BIGGS, P.I. *see* ZAMAN, R., 507
BING, R.F. *see* HEAGERTY, A.M., 539
BIRMINGHAM, A.T. *see* HERBERT, M., 294P
BLACK, A.K., HENSBY, C.N. & GREAVES, M.W. Increased levels of 6-oxo-$PGF_{1\alpha}$ in human skin following ultraviolet B irradiation, 351
BLAIN, P.G., MUCKLOW, J.C., WOOD, P., ROBERTS, D.F. & RAWLINS, M.D. Relative contributions of genetic and environmental factors determining antipyrine clearance, 594P
BLAIR, I.A., LEWIS, P.J., MACDERMOT, J. & SHEPHERD, G.L. Prostacyclin (epoprostenol) binding and activation of adenylate cyclase in normal and diabetic platelets, 581P
BLEIFELD, W. *see* KUPPER, W., 309S
BLOOMFIELD, S.S. *see* FAGAN, T.C., 405
BLOWERS, A.J. *see* DHATARIYA, R.C., 723
BLUMGART, L.H. *see* BRODIE, M.J., 277P
BOBIK, A. *see* JENNINGS, G.L., 257
BODEMAR, G. *see* LARSSON, R., 163
BOEHRINGER, K. *see* WEIDMANN, P., 449S
BOEIJINGA, J.K. *see* DANHOF, M., 379
BOEIJINGA, J.K. *see* JOCHEMSEN, R., 319
BOELAERT, J. *see* THOMIS, J.A., 260
BÖHMER, D. *see* KIRSTEN, R., 397S
BONELLI, J. Relevance of selectivity and non-selectivity in β-adrenoceptor blocking drugs, 199S
BONER, G. *see* ROSENFELD, J., 237S
BOOBIS, A.R. *see* BRODIE, M.J., 277P
BOOBIS, A.R. *see* KAHN, G.C., 594P
BOOBIS, A.R. *see* KAHN, G.C., 637
BOOMSMA, F. *see* MAN IN'T VELD, A.J., 367S
BOOMSMA, F. *see* VINCENT, H.J., 717
BOOTH, L.M. *see* MARLOW, H.F., 269P
BOREUS, L.O., de CHATEAU, P., LINDBERG, C. & NYBERG, L. Terbutaline in breast milk, 731
BORLAND, R.G., NICHOLSON, A.N., SPENCER, M. & STONE, B.M. Hypnotics with single and multicompartment model kinetics: sleep and performance studies in man, 272P
BOWLES, M.J., SUBRAMANIAN, V.B., KHURMI, N.S., DAVIES, A.B. & RAFTERY, E.B. Efficacy of a new calcium channel blocking agent, nicardipine, in chronic stable angina, 590P
BRADBROOK, I.D., JOHN, V.A., MORRISON, P.J., ROGERS, H.J. & SPECTOR, R.G. Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine, 177
BRADSHAW, C.M. *see* MAPLE, S., 584P
BRAN, M. *see* SALHADIN, P., 295S
BRAUN, V. *see* HOMBACH, V., 285S
BRECKENRIDGE, A.M. *see* ADEJPON-YAMOAH, K.K., 829
BRECKENRIDGE, A.M. *see* BACK, D.J., 280P
BRECKENRIDGE, A.M. *see* BACK, D.J., 325
BRECKENRIDGE, A., ORME, M., SERLIN, M.J. & MacIVER, M. Labetalol in essential hypertension, 37S
BREIMER, D.D. *see* DANHOF, M., 379
BREIMER, D.D. *see* JOCHEMSEN, R., 319
BREVETTI, G. *see* CONDORELLI, M., 101S
BRISSE, B., TETSCH, P., JACOBS, W. & BENDER, F. β-Adrenoceptor blockade in stress due to oral surgery, 421S
BRODIE, M.J. Malignant hypertension—a case report, 61
BRODIE, M.J., BOOBIS, A.R., HAMPDEN, C., McPHERSON, G.A.D., BENJAMIN, I.S. & BLUMGART, L.H. Antipyrine and paracetamol metabolism in obstructive jaundice, 277P
BRODIE, M.J. *see* BEEVER, I.W., 599P
BRODIE, M.J. *see* KAHN, G.C. 594P
BRODIE, M.J. *see* KAHN, G.C. 637
BROSSARD, J.-J. *see* MITENKO, P.A., 209
BROWN, M.J., CAUSON, R., MACQUIN, I. & MURPHY, M.B. Facilitation of noradrenergic transmission by neuronally released adrenaline in man, 584P
BROWN, J.J. *see* ATKINSON, A.B., 855
BROWN, J.J. *see* CUMMING, A.M.M., 93S
BROWN, M.J. *see* MURPHY, M.B., 608P
BROWN, M.J. *see* SCRIVEN, A.J.I., 583P
BRYSON, S.M., CAIRNS, C.J. & WHITING, B. Disopyramide pharmacokinetics during recovery from myocardial infarction, 417
BRYSON, S.M., LAWRENCE, J.R., STEELE, W.H., CAMPBELL, B.C., ELLIOTT, H.L. & SUMNER, D.J. The influence of protein binding on disopyramide clearance, 287P
BUCHANAN, N. *see* ROMAN, E.J., 452
BULLINGHAM, R.E.S., McQUAY, H.J., PORTER, E.J.B., ALLEN, M.C. & MOORE, R.A. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis, 665
BULPITT, C.J. Prognosis of treated hypertension 1951–1981, 73
BURGESS, G.W.S. *see* CHAPUT DE SAINTONGE, D.M., 599P
BURROWS, G.D. *see* McINTYRE, I.M., 740
BUSH, M. *see* HAMILTON, M., 441
BUTCHER, M.A., FRAZER, L.A., REDDEL, H.K. & MARLIN, G.E. Dose-dependent pharmacokinetics with

single daily dose slow release theophylline in patients with chronic lung disease, 241
BYE, C. *see* HAMILTON, M., 411

C

CAIRNS, C.J. *see* BRYSON, S.M., 417
CALVERT, R. *see* FEELY, M., 273P
CALVEY, T.N., CHAN, K., MILNE, L.A., MURRAY, G.R. & WILLIAMS, N.E. Plasma concentration of phenoperidine and its pharmacological effects, 293P
CALVEY, T.N. *see* ISHERWOOD, C.N., 612P
CAMPBELL, B.C. Are propranolol and nifedipine synergistic in angina pectoris, 255
CAMPBELL, B.C., ELLIOTT, H.L., REID, J.L. & SHEPHERD, A.N. Prolonged angiotensin-converting enzymne inhibition by captopril in patients with renal failure, 291P
CAMPBELL, B.C., NAISMITH, A., PARIKH, R.K., REID, J.L. & SEWNAUTH, D. A comparison of fentanyl and halothane supplementation to general anaesthesia on the stress response in abdominal surgery, 604P
CAMPBELL, B.C., SHEPHERD, A.N., ELLIOTT, H.L., McLEAN, K. & REID, J.L. Prolonged converting enzyme inhibition following captopril in patients with renal insufficiency, 754
CAMPBELL, B.C., SHEPHERD, A.N. & REID, J.L. Effects of angiotensin converting enzyme inhibitor, captopril, in essential hypertension, 213
CAMPBELL, B.C. *see* BRYSON, S.M., 287P
CAPRA, A. *see* PASOTTI, C., 435S
CARAHER, M.T. *see* MUCKLOW, J.C., 481
CARLSEN, J.E. *see* TRAP-JENSEN, J., 391S
CARRUTHERS, S.G. Cardiac dose-response relationships of oral and intravenous pindolol (visken), 193S
CARVER, J.G *see* PUGH, S.E., 271P
CASHIN, J. *see* WALDEN, R.J., 359S
CASTELLANO, M. *see* AGABITI-ROSEI, E., 87S
CAUSON, R. *see* BROWN, M.J., 584P
CAUSON, R. *see* MURPHY, M.B., 608P
CAUSON, R.C. *see* SCRIVEN, A.J.I., 583P
CAWSON, A.A. *see* STEELE, W.H., 595P
CHAMBERLAIN, D.A. *see* TIMMIS, A.D., 111S
CHAMBERS, D.M., JEFFERSON, G.C., CHAMBERS, M. & LOUDON, N.B. Antipyrine elimination in saliva after low dose combined or progestogen-only oral contraceptive steroids, 223
CHAMBERS, M. *see* CHAMBERS, D.M., 223
CHAN, K. *see* CALVEY, T.N., 293P
CHAN, K. *see* ISHERWOOD, C.N., 612P
CHAPMAN, P.H. & RAWLINS, M.D. A randomized single-blind study of astemizole and chlorpheniramine in normal volunteers, 593P
CHAPMAN, P.H. *see* MUCKLOW, J.C., 481
CHAPUT DE SAINTONGE, D.M. & VERE, D.W. Measurement in clinical trials, 775
CHAPUT DE SAINTONGE, D.M., LEVINE, D.F., SAVAGE, I.T., BURGESS, G.W.S., SHARP, J., MAYHEW, W., SADLER, M., MOODY, R. & GRIFFITHS, R. Three days v 10 days of amoxycillin in otitis media, 599P
CHAPUT DE SAINTONGE, D.M. & VERE, D.W. Methods in clinical pharmacology: clinical trials series, 155
CHAPUT DE SAINTONGE, D.M. *see* HONG, C.Y., 285P
deCHATEAU, P. *see* BOREUS, L.O., 731
CHEN, S-S., PERUCCA, E., LEE, J-N. & RICHENS, A. Serum protein binding and free concentration of phenytoin and phenobarbitone in pregnancy, 547
CHENG, S. *see* HUNT, P.S., 233
CHENG, S. *see* MARLIN, G.E., 445
CHIANG, C.S. *see* DART, A.M., 587P
CHIARIELLO, M. *see* CONDORELLI, M., 101S
CHIERICHETTI, S.M. *see* PASOTTI, C., 435S
CHOW, C.M. *see* MARLIN, G.E., 445
CHRISTENSEN, C.K. *see* ANDREASEN, F., 272P
CHRISTENSEN, N.J. *see* TRAP-JENSEN, J., 391S
CLARK, B.J., MENNINGER, K. & BERTHOLET, A. Pindolol—the pharmacology of a partial agonist, 149S
CLARKE, J.M. *see* McINNES, G.T., 331
CLAYTON, D.G. Ethically optimised designs, 469
CLEGG, R.J. *see* BELL, G.C., 278P
CLIFFORD, J.M., CROSSLEY, D.I., FLOCKHART, I.R. & LLOYD-JONES, G.J. Some effects of oral tolmesoxide in healthy volunteers, 270P
CLIFFORD, J.M., CROSSLEY, D.I., ORWIN, J.M. & PRICE, M. Reversal of some effects of clonidine by RX 781094, an α_2-adrenoceptor antagonist, a pilot study in healthy volunteers, 609P
COHN, J.N., MEHTA, J. & FRANCIS, G.S. Review of the haemodynamic effects of labetalol in man, 19S
COLE, P.J. *see* RUTLAND, J., 679
COLLIER, P.S., KAWAR, P., GAMBLE, J.A.S. & DUNDEE, J.W. Influence of age on pharmacokinetics of midazolam, 602P
COLLIER, P.S. *see* McELNAY, J.C., 501
CONDORELLI, M., BREVETTI, G., CHIARIELLO, M., MICELI, D., LAVECCHIA, G., PAUDICE, G. & VERRIENTI, S. Effects of combined α- and β-blockade by labetalol in patients with coronary heart disease, 101S
CONRADI, E.C. *see* FAGAN, T.C., 405
CONRADI, E.C. *see* FAGAN, T.C., 511
COOK, N. *see* BARNETT, D.B., 284P
COOPER, M. *see* KONG, I., 275P
CORCELLA, J., CRESSEY-VENEZIANO, K., KNOTT, P.J., NICHOLL, D., NIES, A. & ROBINSON, D.S. Effects of phenelzine on plasma free tryptophan during treatment of depression, 295P
CORNSHURWITZ, R.H. *see* FAGAN, T.C., 405
COURVOISIER, F. *see* DAYER, P., 750
COWART, T.D. *see* FAGAN, T.C., 405
CREGEEN, R.J. *see* CRITCHLEY, J.A.J.H., 276P
CRESSEY-VENEZIANO, K. *see* CORCELLA, J., 295P
CRITCHLEY, J.A.J.H., CREGEEN, R.J., BALALI-MOOD, M., PENTLAND, B. & PRESCOTT, L.F. Paracetamol metabolism in heavy drinkers, 276P
CROCKETT, A.J. *see* RUFFIN, R.E., 325S
CROOKS, J. *see* PEDEN, N.R., 835
CROSSLEY, D.I. *see* CLIFFORD, J.M., 270P
CROSSLEY, D.I. *see* CLIFFORD, J.M., 609P
CULIG, J. Saliva theophylline concentrations in a single dose oral study, 296P
CULIG, J., JOHNSTON, A. & TURNER, P. Saliva theophylline concentration after a single oral dose, 243
CUMMING, A.M.M., BROWN, J.J., LEVER, A.F. & ROBERTSON, J.I.S. Intravenous labetalol in treatment of severe hypertension, 93S
CUMMING, A.M.M. *see* ATKINSON, A.B., 855

CUMMING, A.M.M. *see* SONKODI, S., 341
CUMMINGS, A.J. *see* HUSEMEYER, R.P., 171
CURRY, P.V.L. *see* PITCHER, D.W., 711

D

DAL PALU, C., PESSINI, A.C., SEMPLICINI, A., HLEDE, M., MORANDIN, F., PALATINI, P., SPERTI, G. & ROSSI, G.P. Intravenous labetalol in severe hypertension, 97S
DAMMANN, H.G., MÜLLER, P. & SIMON, B. Effect of oral 16, 16-dimethylprostaglandin E_2 on basal acid output in man, 456
DANEELS, R. *see* THOMIS, J.A., 260
DANESHMEND, T.K. & ROBERTS, C.J.C. Short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects, 817
DANESHMEND, T.K. *see* ENE, M.D., 298P
DANHOF, M., VERBEEK, R.M.A., VAN BOXTEL, C.J., BOEIJINGA, J.K. & BREIMER, D.D. Differential effects of enzyme induction on antipyrine metabolite formation, 379
DART, A.M., CHIANG, C.S., ELLIS, M.E., HAWKSWORTH, G.M., JEFFERS, T.A., PARRY, K., SCOTT, A.K. & PETRIE, J.C. Oxprenolol-hydralazine interactions, 587P
DAVENPORT, H.T. *see* HUEMEYER, R.P., 171
DAVIDSON, A.J.L. *see* HUNT, P.S., 233
DAVIES, A.B., SUBRAMANIAN, V.B., GOULD, B.A. & RAFTERY, E.B. Rapid reduction of blood pressure with acute administration of oral labetalol, 588P
DAVIES, A.B., SUBRAMANIAN, V.B., GOULD, B. & RAFTERY E.B. Rapid reduction of blood pressure with acute oral labetalol, 705
DAVIES, A.B. *see* BOWLES, M.J., 590P
DAVIES, C.L., MOLYNEUX, S.G. & NEWMAN, R.J. H.p.l.c. determination of plasma catecholamines in road accident casualties, 283P
DAVIES, D.S. *see* KAHN, G.C., 594P
DAVIES, D.S. *see* KAHN, C.G., 637
DAWLING, S. *see* NAWISHY, S., 612P
DAYER, P., KUBLI, A., KUPFER, A., COURVOISIER, F., BALANT, L. & FAVRE, J. Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers, 750
DE MARNEFFE, M. *see* SALHADIN, P., 295S
DE VENTE, J. *see* HARMS, H.H., 181S
DE WOLFF, F.A. *see* HERFST, M.J., 519
DECOURT, S., FODOR, F., FLOUVAT, B., PRADALIER, A. & DRY, J., Pharmacokinetics of theophylline in night-workers, 567
DEGENHART, W.J. *see* FAGAN, T.C., 405
DELAIGUE-FABRY, R. *see* KANTELIP, J.P., 159S
DENOLIN, H. *see* SALHADIN, P., 295S
DESAI, N.K., KARBHARI, K., PAUL, T., KSHIRSAGAR, N.A. & SHETH, U.K. Prolongation of antipyrine half-life after correction of severe anaemia due to hookworm infestation, 745
DETTLI, J.A. *see* THOMIS, J.A., 260
DEVONSHIRE, H.W. *see* KONG, I., 275P
DHATARIYA, R.C. & BLOWERS, A.J. Effect of pindolol on exercise performance, 723
DHILLON, S., OXLEY, J. & RICHENS, A. Bioavailability of diazepam after intravenous oral and rectal administration in adult epileptic patients, 427
DHILLON, S. & RICHENS, A. Valproic acid and diazepam interaction *in vivo*, 553
DICKINSON, K.E.J. *see* BARNETT, D.B., 284P
DOLLERY, C.T. A clinician looks at the future, 127
DOLLERY, C.T., KOHNER, E.M., LEWIS, P.J. & MURPHY, M.B. Glucose tolerance after 14 years of diuretic therapy, 598P
DOLLERY, C.T. *see* SCRIVEN, A.J.I., 583P
DOLLERY, C.T. *see* WRIGHT, J.M., 847
DOMINIAK, P. & GROBECKER, H. Elevated plasma catecholamines in young hypertensive and hyperkinetic patients: effect of pindolol, 381S
DOROW, P. Effects of β-adrenoceptor blockade on carbohydrate metabolism during exercise—comparison of pindolol and metoprolol, 429S
DOROW, P. Influence of intrinsic sympathomimetic activity (ISA) during β-adrenoceptor blockade in asthmatics, 321S
DOROW, R.G., SEIDLER, J. & SCHNEIDER, H.H. A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites, 561
DOWNEY, K. *see* ILIOPOULOU, I., 611P
DOWNING, I., SHEPHERD, G.L. & LEWIS, P.J. Kinetics of prostacyclin synthetase in umbilical artery microsomes from normal and pre-eclamptic pregnancies, 195
DOYLE, A.E. The introduction of ganglion blocking drugs for the treatment of hypertension, 63
DOYLE, V.M., KELLY, J.G. & O'MALLEY, K. Lymphocyte cAMP production in the elderly: the effects of PGE_1, 266P
DOYLE, V.M., O'MALLEY, K. & KELLY, J.G. Lymphocyte adenylate cyclase activity and sodium fluoride sensitivity in relation to age, 582P
DOYLE, V.M., O'MALLEY, K. & KELLY, J.G. Sodium fluoride activation of human lymphocyte adenylate cyclase is reduced in old age, 871
DRY, J. *see* DECOURT, S., 567
DUBOIS, D., PETITCOLAS, J., TEMPERVILLE, B. & KLEPPER, A. Treatment of hypertension in pregnancy with β-adrenoceptor antagonists, 375S
DUCHENE-MARULLAZ, P. *see* KANTELIP, J.P., 159S
DUNDEE, J.W. & HASSARD, T.H. Some factors influencing the induction dose of thiopentone, 603P
DUNDEE, J.W. *see* COLLIER, P.S., 602P

E

EADIE, M.J. *see* PATTERSON, M., 423
EDWARDS, G. *see* ADJEPON-YAMOAH, K.K., 829
EICHELBAUM, M. *see* PARK, B.K., 737
EIDE, I. *see* LEREN, P., 441S
ELLIOTT, H.L., MEREDITH, P.A., SUMNER, D.J., McLEAN, K. & REID, J.L. Pharmacodynamic and pharmacokinetic assessment of a new β-adrenoceptor antagonist, doxazosin in normotensive patients, 699
ELLIOTT, H.L. *see* BRYSON, S.M., 287P

ELLIOTT, H.L. *see* CAMPBELL, B.C., 754
ELLIOTT, H.L. *see* CAMPBELL, B.C., 291P
ELLIS, M.E. *see* DART, A.M., 587P
ELLIS, W.R. *see* BELL, G.D., 278P
ELVIN, A.T., AXELSON, J.E. & LALKA, D. Tocainide protein binding in normal volunteers and trauma patients, 872
ELWOOD, P.C. Randomised controlled trials: sampling, 631
ENE, M.D., DANESHMEND, T.K., ROBERTS, C.J.C. The inhibitory effects of SCH 28080 on gastric secretion in man, 298P
ERIKSSEN, J., THAULOW, E., MUNDAL, R., OPSTAD, P. & NITTER-HAUGE, S. Comparison of β-adrenoceptor blockers under maximal exercise (pindolol *v* metoprolol *v* atenolol), 201S
ERLANSON, P. *see* LARSSON, R., 163
ESCHALIER, A. *see* KANTELIP, J.P., 159S

F

FABRE, J. *see* DAYER, P., 750
FAGAN, T.C., BLOOMFIELD, S.S., COWART, T.D., CORNSHURWITZ, R.H., LIPICKY, R.J., CONRADI, E.C., HSU, C-Y., GROSSMAN, W.J., HARMON, G.E., DEGENHART, W.J., SINKFIELD, A.W. & GAFFNEY, T.E. Antihypertensive effects of lofexidine in patients with essential hypertension, 405
FAGAN, T.C., WALLE, T., WALLE, U.K., CONRADI, E.C., HARMON, G. & GAFFNEY, T.E. Early kinetics of intravenous propranolol, 511
FAGARD, R., LIJNEN, P. & ANTOON, A. Response of systemic and pulmonary circulation to labetalol at rest and during exercise, 13S
FAGRELL, B. & OSTERGREN, J. Effect of intravenously administered pindolol on skin capillary blood cell velocity in fingers, 233S
FARIELLO, R. *see* AGABITI-ROSEI, E., 87S
FASSBENDER, D. *see* GLEICHMANN, U., 301S
FASSETT, R.G. *see* LAI, K.N., 693
FEELY, M., CALVERT, R. & GIBSON, J. Clobazam in the treatment of catamenial epilepsy, 273P
FEELY, J., McALLISTER, C.B., WILKINSON, G.R. & WOOD, A.J.J. Reduction in lignocaine clearance by cimetidine, 591P
FEELY, J. & WOOD, A.J.J. Reduction in apparent liver blood flow in man by histamine receptor blockers and inhibition of prostaglandin synthesis, 592P
FERRARI, L. *see* MANCIA, G., 27S
FERRY, D.G. *see* WOOD, A.J., 81S
FIORELLA, G. *see* PASOTTI, C., 435S
FISH, A. *see* HASSAN, S.M., 605P
FITSCHA, P., TISO, B., MEISNER, W. & SPITZER, D. The effect of intrinsic sympathomimetic activity of β-adrenoceptor blockers on circadian heart rate, 211S
FITSCHA, P. *see* HITZENBERGER, G., 217S
FITZGERALD, D., GUMBRIELLE, T. & HARRY, J.D. Effects in man of ICI 118551 (a selective β_2-adrenoceptor blocking drug) on some cardiovascular responses induced by isoprenaline, 586P
FLABEAU, C. *see* THIBONNIER, M., 533
FLANAGAN, R.J., HARRIS, L., HOLT, D.W., McKENNA, W.J., ROWLAND, E. & STOREY, G.C.A. High performance liquid chromatographic measurement of amiodarone and its desethyl metabolite in plasma, 281P
FLOCKART, I.R. *see* CLIFFORD, J.M., 270P
FLOUVAT, B. *see* DECOURT, S., 567
FLOUVAT, B. *see* THIBONNIER, M., 533
FODOR, F. *see* DECOURT, S., 567
FORSGREN, A. *see* HALLENGREN, B., 543
FORSYTH, J.S., MORELAND, T.A. & RYLANCE, G.W. Effect of fever on antipyrine metabolism in children, 811
FOSS, O.P. *see* LEREN, P., 441S
FOWLE, A.S.E. *see* WHITEMAN, P.D., 743
FOWLER, M.B. *see* TIMMIS, A.D., 111S
FRANCIS, G.S. *see* COHN, J.N., 19S
FRANSSON, L. *see* LARSSON, R., 163
FRASER, R. *see* ATKINSON, A.B., 855
FRASER, R. *see* SONKODI, S., 341
FRAZER, L.A. *see* BUTCHER, M.A., 241
FREESTONE, S. & RAMSAY, L.E. Haemodynamic effects of cigarette smoking during β-adrenoceptor blockade, 258
FREESTONE, S., RAMSAY, L.E. & SILAS, J.H. Incidence of hydralazine-associated autoimmune disease, 291P
FREESTONE, S., SILAS, J.H. & RAMSAY, L.E. Sample size for short-term trials of antihypertensive drugs, 292P
FREIS, E.D. The Veterans trial and sequelae, 67
FREY, B.M. & FREY, F.J. Estimation of transcortin concentration by measurements of plasma protein binding of prednisolone and electroimmunodiffusion, 245
FREY, F.J. *see* FREY, B.M., 245
FROHNAPFEL, F. *see* GUNDERT-REMY, U., 795

G

GACHOKA, C. *see* JUMA, F.D., 615P
GAFFNEY, T.E. *see* FAGAN, T.C., 405
GAFFNEY, T.E. *see* FAGAN, T.C., 511
GAGNON, M.A. *see* SPENARD, J., 752
GAMBLE, J.A.S. *see* COLLIER, P.S., 602P
GAMBLES, S.A. *see* STARK, R.D., 600P
GARLE, M. *see* TOMSON, G., 653
GERBER, J.G. *see* MOLINOFF, P.B., 365S
GIBBERD, F.B., SPENCER, K.M., WEBLEY, M. & BERRY, D. A comparison of the bioavailability of two brands of phenytoin, 455
GIBSON, J. *see* FEELY, M., 273P
GIL-SANCHEZ, D. *see* HOMBACH, V., 285S
GITAU, W. *see* JUMA, F.D., 615P
GJÖRES, J.E. *see* THULESIUS, O., 229S
GLEICHMANN, U., FASSBENDER, D., TRIEB, G., MANNEBACH, H. & OHLMEIER, H. The influence of β-adrenoceptor antagonists with and without intrinsic sympathomimetic activity on local wall motion abnormalities in patients with coronary heart disease, 301S
GOENS, M.B. *see* MOLINOFF, P.B., 365S
GOOPTU, D. *see* BATEMAN, D.N., 675
GOULD, B. *see* DAVIES, A.B., 705
GOULD, B.A. *see* DAVIES, A.B., 588P
GRAHAM, B.R. *see* WALDEN, R.J., 359S

GRAHAME-SMITH, D.G. *see* ARONSON, J.K., 606P
GRAHAME-SMITH, D.G. *see* PUGH, S.E., 271P
GRAHNEN, A. *see* SEIDEMAN, P., 865
GRASSI, F. *see* MANCIA, G., 27S
GREAVES, M.W. *see* BLACK, A.K., 351
GREEN, A.F. Discovery of bretylium and bethanidine, 25
GREENWOOD, D. & SLACK, R. Urinary tract infection, 619
GRIFFIN, J.P. & STEWART, A.G. Six months experience of new procedures affecting conduct of clinical trials in UK, 253
GRIFFIN, W. *see* RUTLAND, J., 679
GRIFFITHS, R. *see* CHAPUT DE SAINTONGE, D.M., 599P
GROBECKER, H. *see* DOMINIAK, P., 381S
GROSS, F. Can we develop new drugs for hypertension, 133
GROSS, F. Place of β-adrenoceptor and β-adrenoceptor blockade in treatment of hypertension, 5S
GROSSMAN, W.J. *see* FAGAN, T.C., 405
GUBRANDSSON, T. *see* SVENSSON, A., 259S
GIUDICELLI, J.F. & LHOSTE, F. β-Adrenoceptor blockade and atrioventricular conduction in dogs. Role of intrinsic sympathomimetic activity, 167S
GIUDICELLI, J.F. *see* BERDEAUX, A., 175S
GUMBRIELLE, T. *see* FITZGERALD, D., 586P
GUNDERT-REMY, U., FROHNAPFEL, F., JOURDAN, E., WEBER, E. & STIEHL, A. Estimation of biliary excretion of ureidopenicillins in healthy volunteers using marker dilution technique, 95

H

HAGLUND, K. *see* SEIDEMAN, P., 865
HAHN, B. & STRAUER, B.E. The influence of β-adrenoceptor blockade on left ventricular function, 305S
HALLENGREN, B., FORSGREN, A. & MELANDER, A. Influence of β-adrenoceptor blocking agents on lymphocyte function *in vitro*, 543
HALLIS, K.F. *see* ARONSON, J.K., 606P
HALLYNK, T. *see* THOMIS, J.A., 260
HAMER, J. *see* JOHNSTON, A., 288P
HAMER, J. *see* JOHNSTON, A., 606P
HAMILTON, M., BUSH, M., BYE, C. & PECK, A.W. A comparison of triprolidine and cyclizine on histamine (H_1) antagonism, subjective effects and performance tests on man, 441
HAMILTON, M., PECK, A.W. & SMITH, P. Procyclidine and atropine: comparison of anticholinergic effects in man, 614P
HAMM, C.W. *see* KUPPER, W., 309S
HAMPDEN, C. *see* BRODIE, M.J., 277P
HAMPTON, J.R. *see* WILCOX, R.G., 841
HANSSON, L. *see* SVENSSON, A., 259S
HARDMAN, J. *see* HURLOW, R.A., 803
HARMON, G.E. *see* FAGAN, T.C., 405
HARMON, G. *see* FAGAN, T.C., 511
HARMS, H.H., DE VENTE, J. & ZAAGSMA, J. β-Adrenoceptor blocking agents and lipolysis, 181S
HARRIS, L. *see* FLANAGAN, R.J., 281P
HARRISON, I.R. *see* McINNES, G.T., 187
HARRISON, I.R. *see* McINNES, G.T., 331
HARRISON, I.R. *see* McINNES, G.T., 596P
HARRISON, I.R. *see* McINNES, G.T., 513
HARRON, D.W.G., ARNDTS, D. & SHANKS, R.G. Alinidine pharamcokinetics following acute and chronic dosing, 821
HARRY, J.D. *see* FITZGERALD, T., 586P
HARTLING, O.J. *see* TRAP-JENSEN, J., 391S
HASSAN, S.M., OLIVESI, A. & FISH, A. A comparison of antrafenine and aspirin on frusemide diuresis and platelet aggregation, 605P
HASSARD, T.H. *see* DUNDEE, J.W., 603P
HATHWAY, N. *see* NAWISHY, S., 295P
HAWKSWORTH, G.M. *see* DART, A.M., 587P
HEAGERTY, A.M., RUSSELL, G.I., BING, R.F., THURSTON, H. & SWALES, J.D. The addition of prazosin to standard triple therapy in the treatment of severe hypertension, 539
HEAZELWOOD, R. *see* PATTERSON, M., 423
HEIKKILÄ, J. & NIEMINEN, M.S. Acute myocardial infarction: selective or ISA-type β-adrenoceptor blocking drug, 299S
HEINTZ, *see* KIRSTEIN, R., 397S
HELGELAND, A. *see* LEREN, P., 441S
HELLER, K.B. *see* BARNETT, D.B., 613P
HENDERSON, A.H. *see* BASHIR, A., 287P
HENDERSON, D.B. *see* MUCKLOW, J.C., 481
HENDERSON, D.B. *see* WOODHOUSE, K.W., 605P
HENRIKSEN, *see* KJAER, M., 487
HENSBY, C.N. *see* BLACK, A.K., 351
HERBERT, M., STENDEN, P.J., SHORT, A.H. & BIRMINGHAM, A.T. Psychopharmacological evaluation of DL308 in healthy volunteers, 294P
HERFST, M.J. & DE WOLFF, F.A. Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients, 519
HIETANEN, E. *see* LEHTONEN, A., 445S
HIGUMA, K. *see* TSUKIYAMA, H., 269S
HILGER, H.H. *see* HOMBACH, V., 285S
HILLIS, W.S. *see* WHITING, B., 529
HILPERT, F. *see* VALETTE, H., 250
HIND, I.S. *see* RUDGE, S.R., 448
HIRAYAMA, H. *see* TSUJIMOTO, G., 493
HITZENBERGER, G., FITSCHA, P., BEVERIDGE, T., NÜESCH, E. & PACHA, W. Effects of age and smoking on the pharmacokinetics of pindolol and propranolol, 217S
HJERMANN, I. *see* LEREN, P., 441S
HLEDE, M. *see* DAL PALU, C., 97S
HOLME, I. *see* LEREN, P., 441S
HOLMES, J., STEVENS, A.J. & VERE, D.W. Anticipating the numbers of subjects in a clinical trial, 274P
HOLMES, J. *see* VANDENBURG, M.J., 747
HOLT, D.W. *see* BAXTER, R., 591P
HOLT, D.W. *see* FLANAGAN, R.J., 281P
HOLT, J.E., KAYE, C.M. & SANKEY, M.G. Sensitive high-performance liquid chromatographic assay methods for monitoring methotrimeprazine and dimethothiazine levels in plasma, 282P
HOLT, J.E. *see* SANKEY, M.G., 578
HOMBACH, V., BRAUN, V., HOPP, H.-W., GIL-SANCHEZ, D., BEHRENBECK, D.W., TAUCHERT, M. & HILGER, H.H. Electrophysiological effects of cardioselective and non-cardioselective β-adrenoceptor blockers with and without ISA at rest and during exercise, 285S
HONG, C.Y., CHAPUT DE SAINTONGE, D.M. & TURNER, P. Comparison of local anaesthetic effects of (+)-pro-

pranolol, (±)-propranolol and procaine on human sperm, 285P
HÖPP, H.-W. *see* HOMBACH, V., 285S
HORAI, Y., ISHIZAKI, T., SASAKI, T., KOYA, G., MATSUYAMA, K. & IGUCHI, S. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects, 361
HOUBEN, H., THEIN, TH. & VAN'T LAAR, A. Haemodynamic effects of cigarette smoking during β-adrenoceptor blockade—a reply, 259
HSU, C-Y. *see* FAGAN, T.C., 405
HUGHES, R., AL-AZAWI, S. & PAYNE, J.P. Tachyphylaxis after repeated dosage of decamethonium in anaesthetized man, 355
HUNT, P.S., DAVIDSON, A.J.L., ALDEN, J. & CHENG, S. Bile and serum levels of tinidazole after a single oral dose, 233
HUNTER, K.R. *see* BENFIELD, G.F.A., 219
HURLOW, R.A., AUKLAND, A., HARDMAN, J. & WHITTINGTON, J.R. Studies of haemodynamic effects of creatine phosphate in man, 803
HUSEMEYER, R.P., CUMMINGS, A.J., ROSANKIEWICZ, J.R. & DAVENPORT, H.T. Study of pethidine kinetics and analgesia in women in labour following intravenous, intramuscular and epidural administration, 171
HUTTON, I. *see* TWEDDEL, A.C., 256
HUTTUNEN, J.K. *see* MIETTINEN, T.A., 431S

I

IBRAHEEM, J.J. *see* TEELT-MANSEN, P., 239
IDLE, J.R. *see* KONG, I., 275P
IGUCHI, S. *see* HORAI, Y., 361
ILIOPOULOU, A. & DOWNEY, K. Erythromycin kinetics in patients on haemodialysis, 611P
IND, P.W. *see* MURPHY, M.B., 608P
ING, R. *see* TOMSON, G., 653
INGS, R.M.G., LAWRENCE, J.R., McDONALD, A., McEWEN, J., PIDGEN, A.W. & ROBINSON, J.D. Glibenclamide pharmacokinetics in healthy volunteers: evidence for zero-order drug absorption, 264P
ISHERWOOD, C.N., MURRAY, G.R., CHAN, K., CALVEY, T.N. & WILLIAMS, N.E. The effect of liver disease on the metabolism and elimination of phenoperidine in man, 612P
ISHIZAKI, T. *see* HORAI, Y., 361
ISHIZAKI, T. *see* TSUJIMOTO, G., 493
ISLES, T.E. *see* PEDEN, N.R., 835

J

JACK, D.B. *see* KENDALL, M.J., 393
JACKSON, P.R., RAMSAY, L.E. & WAKEFIELD, V. Relative potency of potassium chloride, triamterene and spironolactone in thiazide-induced hypokalaemia, 597P
JACKSON, P.R., TUCKER, G.T. & WOODS, H.F. Plasma binding of drugs in patients with cancer, 263P
JACOBS, W. *see* BRISSE, B., 421S
JAGGARAO, N.S.V. *see* TIMMIS, A.D., 111S
JAGGER, C. *see* BARNETT, D.B., 613P
JAKOBSEN, F.K. *see* ANDREASEN, F., 272P
JAMES, O.F.W. *see* WILLIAMS, F.M. 595P
JAMIESON, R. *see* BAXTER, R., 591P
JANSEN, J. *see* ANDREASEN, F., 272P
JEE, L. *see* OPIE, L.H., 115S
JEFFERS, T.A. *see* DART, A.M., 587P
JEFFERSON, G.C. *see* CHAMBERS, D.M., 223
JENNINGS, G.L., BOBIK, A. & KORNER, P.I. Influence of intrinsic sympathomimetic activity of β-adrenoceptor blockers on heart rate and blood pressure responses to graded exercise, 257
JENNINGS, G.L. *see* LITTLE, P.J., 78S
JOCHEMSEN, R., VAN DER GRAAFF, M., BOEIJINGA, J.K. & BREIMER, D.D. Influence of sex, menstrual cycle and oral contraceptives on the disposition of nitrazepam, 319
JOHN, V.A. *see* BENNETT, P.N., 387
JOHN, V.A. *see* BRADBROOK, I.D., 177
JOHN, V.A. *see* KENDALL, M.J., 393
JOHNSTON, A. & HAMER, J. Serum protein binding of disopyramide, 288P
JOHNSTON, A., MUHIDDIN, K.A. & HAMER, J. Serum protein binding of flecainide, 606P
JOHNSTON, A. *see* CULIG, J., 243
JOHNSTON, G.D., NICHOLLS, D.P. & LEAHEY, W.J. The acute non-diuretic vascular responses of frusemide in man: dose-response characteristics, 589P
JOSEFSSON, K., BERGAN, T. & MAGNI, L. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base, 685
JOURDAN, E. *see* GUNDERT-REMY, U., 795
JOYCE, C.R.B. Placebos and other comparative treatments, 313
JUMA, F.D., GACHOKA, C. & GITAU, W. Evaluation of diabetic control in Kenyan black Africans on various treatments using the HBA_{1c}, 615P

K

KAHN, A.K.A., TRUELOVE, S.C. & ARONSON, J.K. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man, 523
KAHN, G.C., BOOBIS, A.R., MURRAY, S., BRODIE, M.J. & DAVIES, D.S. Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver, 637
KAHN, G.C., BOOBIS, A.R., MURRAY, S., PLUMMER, W., BRODIE, M.J. & DAVIES, D.S. Enzymatic basis for the defective, 4-hydroxylation of debrisoquine, 594P
KAMPMANN, J. & MØLHOLM-HANSEN, J.E. Creatinine clearance, different methods of determination—a reply, 261
KANE, J.A. Labetalol in general practice, a review, 59S
KANEKO, Y. *see* TAKEDA, T., 49S
KANTELIP, J.P., DUCHENE-MARULLAZ, P., DELAIGUE-FABRY, R. & ESCHALIER, A. Comparison of the effects of propranolol, pindolol, oxprenolol and acebutolol on

atrioventricular conduction in unanaesthetised dogs, 159S
KANTO, J., SELLMAN, R. & LAURIKAINEN, E. Saliva concentrations of lignocaine in healthy volunteers, 736
KARBHARI, K. *see* DESAI, N.K., 745
KASS, E.H. Special clinics for hypertension—the role of the Hypertension Detection and Follow-up Programme, 81
KATTWINKEL, W. *see* RIECKERT, H., 227S
KAWAR, P. *see* COLLIER, P.S., 602P
KAYE, C.M. *see* HOLT, J.E., 282P
KAYE, C.M. *see* SANKEY, M.G., 578
KELLY, J.G. *see* DOYLE, V.M., 266P
KELLY, J.G. *see* DOYLE, V.M., 582P
KELLY, J.G. *see* DOYLE, V.M., 871
KELMAN, A.W. *see* WHITING, B., 529
KELMAN, A.W. *see* WHITING, B., 610P
KENDALL, M.J., JACK, D.B., WOODS, K.L., LAUGHER, S.J., QUARTERMAN, C.P. & JOHN, V.A. Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros® delivery system, 393
KENDALL, M.J. *see* ZAMAN, R., 507
KERP, L. *see* SCHLÜTER, K.J., 407S
KHOUW, V. *see* NARANJO, C.A., 575
KHURMI, N.S. *see* BOWLES, M.J., 590P
KINCAID-SMITH, P. Renal pathology in hypertension and the effects of treatment, 107
KING, D.J. *see* STEELE, W.H., 595P
KINNEY, C.D. *see* SALEM, S.A.M., 601P
KINNEY, C.D. *see* TAYLOR, D.R., 569
KIRSTEN, R., HEINTZ, B., BÖHMER, D., NELSON, K., ROTH, S. & WELZEL, D. Relationship of plasma catecholamines to blood pressure in hypertensive patients during β-adrenoceptor blockade with and without intrinsic sympathomimetic activity, 397S
KJAER, M., HENRIKSEN, H. & KNUDSEN, J. A comparative study of intramuscular buprenorphine and morphine in the treatment of chronic pain of malignant origin, 487
KJELDSEN, S.E. *see* LEREN, P., 441S
KLEPPER, A. *see* DUBOIS, D., 375S
KNOTT, P.J. *see* CORCELLA, J., 295P
KNUDSEN, J. *see* KJAER, M., 487
KOHLSCHÜTTER, S. *see* SZÉCSI, E., 353S
KOHNER, E.M. *see* DOLLERY, C.T., 598P
KONG, I., DEVONSHIRE, H.W., COOPER, M., SLOAN, T.P., IDLE, J.R. & SMITH, R.L. The influence of oxidation phenotype on phenacetin metabolism and haemotoxicity, 275P
KORNER, P.I. Circulatory regulation in hypertension, 95
KORNER, P.I. *see* JENNINGS, G.L., 257
KOVACS, I.B. & O'GRADY, J. Prostacyclin increases filterability of normal fresh and stored human red blood cells, 298P
KSHIRSAGAR, N.A. *see* DESAI, N.K., 745
KUBLI, A. *see* DAYER, P., 750
KUGLER, G. The effect of pindolol on myocardial release of inosine hypoxanthine and lactate during pacing-induced angina, 313S
KUMLIN, T. *see* MIETTINEN, T.A., 431S
KUPFER, A. *see* DAYER, P., 750
KUPPER, W., HAMM, C.W. & BLEIFELD, W. The effect of pindolol on myocardial blood flow, metabolism and function during rest and pacing in patients with coronary heart disease, 309S
KUSS, A. *see* RIECKERT, H., 227S

L

LAI, C.L. *see* WANG, C., 791
LAI, K.N., FASSETT, R.G. & MATHEW, T.H. Effect of long-term cimetidine treatment of left ventricular function in haemodialysis patients with active hyperparathyroidism, 693
LALKA, D. *see* AXELSON, J.E., 872
LAM, K.C. *see* WANG, C., 791
LAMBERT, J.B. *see* ROMAN, E.J., 452
LANG, E. *see* SZÉCSI, E., 353S
LANGLOIS, S. *see* RANGNO, R.E., 345S
LARSSON, R., ERLANSON, P., BODEMAR, G., WALAN, A., BERTLER, A., FRANSSON, L. & NORLANDER, B. Pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function, 163
LATIMER, K.M. *see* RUFFIN, R.E., 325S
LAUGHER, S.J. *see* KENDALL, M.J., 393
LAURILAINEN, E. *see* KANTO, J., 736
LAVECCHIA, G. *see* CONDORELLI, M., 101S
LAWRENCE, J.R., McEWEN, J., PIDGEN, A.W. & ROBINSON, J.D. Dose response characteristics of D-Ser (TBU)^6 Des Gly 10-LHRH-ethylamide (Hoe 766-'Buserelin') following intranasal administration to five healthy patients, 287P
LAWRENCE, J.R. *see* BRYSON, S.M., 287P
LAWRENCE, J.R. *see* INGS, R.M.J., 264P
LEAHEY, W.J. *see* JOHNSTON, G.D., 589P
LECKIE, B. *see* ATKINSON, A.B., 855
LECKIE, B.J. *see* SONKODI, S., 341
LEDERMANN, H. *see* WHITING, B., 529
LEE, E.J.D. & LEE, L.K.H. A simple pharmacokinetic method for separating the three acetylation phenotypes; a preliminary report, 375
LEE, J-N. *see* CHEN, S-S., 547
LEE, L.K.H. *see* LEE, E.J.D., 375
LEES, L.J. *see* MAUDGAL, D.P., 279P
LEHTONEN, A., HIETANEN, E., MARNIEMI, J., PELTONEN, P. & NISKANEN, J. Effect of pindolol on serum lipids and lipid metabolizing enzymes, 445S
LEREN, P., EIDE, I., FOSS, O.P., HELGELAND, A., HJERMANN, I., HOLMS, I., KJELDSEN, S.E. & LUND-LARSEN, P.G. Antihypertensive drugs and blood lipids: the Oslo study, 441S
LEVER, A.F. *see* ATKINSON, A.B., 855
LEVER, A.F. *see* CUMMING, A.M.M., 93S
LEVINE, D.F. *see* CHAPUT DE SAINTONGE, D.M., 599P
LEWIS, M.J. *see* BASHIR, A., 287P
LEWIS, P.J. *see* BLAIR, I.A., 581P
LEWIS, P.J. *see* DOLLERY, C.T., 598P
LEWIS, P.J. *see* DOWNING, I., 195
LHOSTE, F. *see* GIUDICELLI, J.F., 167S
LINDBERG, C. *see* BOREUS, L.O., 731
LINDSTROM, B. *see* LONNERHOLM, G., 729
LINDSTROM, B. *see* SEIDEMAN, P., 865
LINEN, P. *see* FAGARD, R., 13S
LIPICKY, R.J. *see* FAGAN, T.C., 405
LITTLE, P.J., JENNINGS, G.L., SKEWS, H. & BOBIK, A. Bioavailability of dihydroergotamine in man, 785
LLOYD-JONES, G.J. *see* CLIFFORD, J.M., 270P
LLOYD-JONES, J.K. *see* RUDGE, S.R., 448
LOHMÖLLER, G. & STOCKER, K. Can ISA compensate for bradycardia due to β-adrenoceptor blockade, 315S

LONGRIGG, J.N. The upper urinary tract, 461
LÖNNERHOLM, G. & LINDSTRÖM, B. Terbutaline excretion into breast milk, 729
LOUDON, N.B. *see* CHAMBERS, D.M., 223
LOUIS, W.J. & McNEIL, J.J. β-Adrenoceptor blocking drugs: the relevance of intrinsic sympathomimetic activity, 317S
LOUIS, W.J. *see* McNEIL, J.J., 75S
LUBBE, W.F. *see* OPIE, L.H., 115S
LUND-LARSEN, P.G. *see* LEREN, P., 441S

Mc

McALLISTER, C.B. *see* FEELY, J., 591P
McDEVITT, D.G. *see* ARNOLD, J.M.O., 266P
McDEVITT, D.G. *see* ARNOLD, J.M.O., 585P
McDEVITT, D.G. *see* SALEM, S.A.M., 601P
McDEVITT, D.G. *see* TAYLOR, D.R., 569
McDONALD, A. *see* INGS, R.M.F., 264P
McELNAY, J.C. & TEMPLE, D.J. The use of buccal partitioning as a model to examine the effects of aluminium hydroxide gel on the absorption of propranolol, 399
McELNAY, J.C., UPRICHARD, G. & COLLIER, P.S. The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin, 501
McEWEN, J. *see* INGS, R.M.J., 264P
McEWEN, J. *see* LAWRENCE, J.R., 297P
McLEAN, K., *see* CAMPBELL, B.C., 754
McLEAN, K. *see* ELLIOTT, H.L., 699
McLEAN, K. *see* RUBIN, P.C., 290P
McLEAN, K. *see* SCOTT, P.C., 235
McINNES, G.T., PERKINS, R.M., SHELTON, J.R & HARRISON, I.R. Spironolactone dose-response relationships after single and repeated administrations, 596P
McINNES, G.T., PERKINS, R.M., SHELTON, J.R. & HARRISON, I.R. Spironolactone dose-response relationships in healthy subjects, 513
McINNES, G.T., SHELTON, J.R., HARRISON, I.R., PERKINS, R.M. & PALMER, R.F. Comparison of prorenoate potassium and spirolactone after repeated doses and steady-state plasma levels of active metabolites, 187
McINNES, G.T., SHELTON, J.R., RAMSEY, L.E., HARRISON, I.R., ASBURY, M.J., CLARKE, J.M., PERKINS, R.M. & VENNING, G.R. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience, 331
McINTYRE, E.L.M. *see* RUFFIN, R.E., 325S
McINTYRE, I.M., NORMAN, T.R., BURROWS, G.D. & MAGUIRE, K.P. Pharmacokinetics of nomifensine after a single oral dose, 740
McKENNA, W.J. *see* FLANAGAN, R.J., 281P
McKENZIE, J.K. *see* MITENKO, P.A., 209
McNIEL, J.J., ANDERSON, A.E., LOUIS, W.J. & RAYMOND, K. Labetalol steady-state pharmacokinetics in hypertensive patients, 75S
McNEIL, J.J. *see* LOUIS, W.J., 317S
McPHERSON, G.A.D. *see* BRODIE, M.J., 277P
McQUAY, H.J. *see* BULLINGHAM, R.E.S., 665

M

MACDERMOT, J. *see* BLAIR, I.A., 581P
MACGREGOR, G.A., BANKS, R.A., MARKANDU, N.D. & ROULSTON, J. Xipamide and cyclopenthiazide in essential hypertension—comparative effects of blood pressure and plasma potassium, 859
MACHAEL, C.A. Evaluation of labetalol in treatment of hypertension complicating pregnancy, 127S
MACIVER, M. *see* BACK, D.J., 280P
MACIVER, M. *see* BACK, D.J., 325
MACIVER, M. *see* BRECKENRIDGE, A., 37S
MACQUIN, I. *see* BROWN, M.J., 584P
MACQUIN, I. *see* SCRIVEN, A.J.I., 583P
MAGNANI, B. *see* MALINI, P.L., 123S
MAGNI, L. *see* JOSEFSSON, K., 685
MAGUIRE, K.P. *see* McINTYRE, I.M., 740
MALINI, P.L., STROCCHI, E., NEGRONI, S., AMBROSIONI, E. & MAGANI, B. Renal haemodynamics after chronic treatment with labetalol and propranolol, 123S
MAN IN'T VELD, A.J., BOOMSMA, F. & SCHAELEKAMP, M.A.D.H. Effects of β-adrenoceptor agonist and antagonists in patients with peripheral autonomic neuropathy, 367S
MAN IN'T VELD, A.J. & SCHALEKAMP, M.A.D.H. How intrinsic sympathomimetic activity modulates the haemodynamic responses to β-adrenoceptor antagonists. A clue of the nature of their antihypertensive mechanism, 245S
MAN IN'T VELD, A.J. *see* VINCENT, H.H., 717
MANCIA, G., POMIDOSSI, G., PARATI, G., BERTINIERI, G., GRASSI, F., NAVONE, A., FERRARI, L., GREGORINI, L. & ZANCHETTI, A. Blood pressure response to labetalol in twice and three times daily administration, 27S
MANNEBACH, H. *see* GLEICHMANN, U., 301S
MAPLE, S., BRADSHAW, C.M. & SZABADI, E. The responsiveness of sweat glands to phenylephrine and carbachol in anxiety, 584P
MARKANDU, N.D. *see* MACGREGOR, G.A., 859
MARLIN, G.E., THOMPSON, P.J., REDELL, H.K., CHOW, C.M. & CHENG, S. Bronchodilator activity of prazosin in patients with allergic rhinitis and asthma, 445
MARLIN, G.E. *see* BUTCHER, M.A., 241
MARLOW, H.F., WARDLEWORTH, A.G. & BOOTH, L.M. The haemodynamic effects of oral doses of ICI 118, 587, a β-adrenoceptor partial agonist, in healthy volunteers, 269P
MARNIEMI, J. *see* LEHTONEN, A., 445S
MATHEW, T.H. *see* LAI, K.N., 693
MATSUYAMA, K. *see* HORAI, Y., 361
MATTILA, S. *see* MIETTINEN, T.A. 431S
MAUDGAL, D.P., MAXWELL, J.D., LEES, L.J. & WILD, R.N. Comparison of plasma and bile concentrations of amoxycillin and ceftriaxone (Rocephin) after bolus intravenous administration, 279P
MAWER, G.E. Dosage adjustment in renal insufficiency, 145
MAXWELL, J.D. *see* MAUDGAL, D.P., 279P
MAXWELL, R.A. Guanethidine after twenty years: a pharmacologist's perspective, 35
MAYHEW, S. *see* CHAPUT DE SAINTONGE, D.M., 599P

MEHTA, J. *see* COHN, J.N., 19S
MEIER, A. *see* WEIDMANN, P., 449S
MEISNER, W. *see* FITSCHA, P., 211S
MELANDER, A. *see* HALLENGREN, B., 543
MENARD, J. *see* THIBONNIER, M., 533
MENNINGER, K. *see* CLARK, B.J., 149S
MEREDITH, P.A. *see* ELLIOTT, H.L., 699
MICELI, D. *see* CONDORELLI, M., 101S
MIDDLETON, B. *see* BELL, G.D., 278P
MIDDLETON, D. *see* WILLIAMS, F.M. 595P
MIETTINEN, T.A., VANHANEN, H., HUTTUNEN, J.K., NAUKKARINEN, V., MATTILA, S., STRANDBERG, T. & KUMLIN, T. HDL cholesterol and β-adrenoceptor blocking agents in a 5 year multifactorial primary prevention trial, 431S
MILNE, L.A. *see* CALVEY, T.N., 293P
MITENKO, P.A., McKENZIE, J.K. & BROSSARD, J.-J. Antihypertensive action of acebutolol when used comcomitantly with hydrochlorothiazide, 209
MOGENSEN, C.E. *see* ANDREASEN, F., 272P
MØLHOLM-HANSEN, J.E. *see* KAMPMANN, J., 261
MOLINOFF, P.B., AARONS, R., NIES, A.S., GERBER, J.G., WOLFE, B.B. & GOENS, M.B. Effects of propranolol on β-adrenergic receptors on human lymphocytes, 365S
MOLYNEUX, S.G. *see* DAVIES, C.L., 283P
MONTINI, E. *see* AGABITI-ROSEI, E., 87S
MOODY, R. *see* CHAPUT DE SAINTONGE, D.M., 599P
MOORE, R.A. *see* BULLINGHAM, R.E.S., 665
MORANDIN, F. *see* DAL PALU, C., 97S
MORDASINI, R. *see* WEIDMANN, P., 449S
MORELAND, T.A., PRIESTMAN, D.A. & RYLANCE, G.W. Saliva carbamazepine levels in children before and during multiple dosing, 647
MORELAND, T.A. *see* FORSYTH, J.S., 811
MORLAND, J. *see* OLSEN, H., 203
MORRISON, P.J. *see* BRADBROOK, I.D., 177
MORTON, J.J. *see* ATKINSON, A.B., 855
MORTON, J.J. *see* SONKODI, S., 341
MUCKLOW, J.C., CARAHER, M.T., HENDERSON, D.B., CHAPMAN, P.H., ROBERTS, D.F. & RAWLINS, M.D. The relationship between individual dietary constituents and antipyrine metabolism in Indo-Pakistani immigrants to Britain, 481
MUCKLOW, J.C. *see* BLAIN, P.G., 594P
MUHIDDIN, K.A. *see* JOHNSTON, A., 606P
MUIESAN, G. *see* AGABITI-ROSEI, E., 87S
MUIESAN, M.L. *see* AGABITI-ROSEI, E., 87S
MÜLLER, P. *see* DAMMANN, H.G., 456
MUNDAL, R. *see* ERIKSSEN, J., 201S
MURPHY, M.B., BROWN, M.J., CAUSON, R., IND, P.W. & SCRIVEN, A.J. The effect of pentolinium on plasma catecholamines in hypertensives and normal controls, 608P
MURPHY, M.B. *see* BROWN, M.J., 584P
MURPHY, M.B. *see* DOLLERY, C.T., 598P
MURPHY, M.B. *see* SCRIVEN, A.J.I. 583P
MURRAY, G.R. *see* CALVEY, T.N., 293P
MURRAY, G.R. *see* ISHERWOOD, C.N., 612P
MURRAY, R.G. *see* TWEDDEL, A.C., 256
MURRAY, S. *see* KAHN, G.C., 594P
MURRAY, S. *see* KAHN, G.C., 637
MUSUYAMA, Y. *see* TAKEDA, T., 49S

N

NAISMITH, A. *see* CAMPBELL, B.C., 604P
NAHORSKI, S.R. *see* BARNETT, D.B., 284P
NARANJO, C.A., SELLERS, E.M. & KHOUW, V. Unaltered serum propranolol binding by meal-induced variations in fatty acids, 575
NAUKKARINEN, V. *see* MIETTINEN, T.A., 431S
NAVONE, A. *see* MANCIA, G., 27S
NAWISHY, S. & DAWLINGS, S. Kinetic interaction of mianserin in epileptic patients on anticonvulsant drugs, 612P
NAWISHY, S. & HATHWAY, N. Nomifensine pharmacokinetics in patients with epilepsy, 295P
NEGRONI, S. *see* MALINI, P.L., 123S
NELSON, G.I.C., SILKE, B. & TAYLOR, S.H. Haemodynamic dose-response effects of labetalol in coronary heart disease, 589P
NELSON, G.I.C. *see* AHUJA, R., 610P
NELSON, G.I.C. *see* TAYLOR, S.H., 590P
NELSON, K. *see* KIRSTEN, R., 397S
NEWMAN, R.J. *see* DAVIES, C.L., 283P
NICHOLL, D. *see* CORCELLA, J., 295P
NICHOLLS, D.P. *see* JOHNSTON, G.D., 589P
NICHOLSON, A.N. & STONE, B.M. Hypnotic activity and effects on performance of lormetazepam and camazepam—analogues of temazepam, 433
NICHOLSON, A.N. & STONE, B.M. Peformance studies with the H_1-histamine receptor antagonists, astemizole and terfenadine, 199
NICHOLSON, A.N. & STONE, B.M. Sleep and antidepressants: studies with mianserin hydrochloride and nomifensine, 603P
NICHOLSON, A.N. *see* BORLAND, R.G., 272P
NIEMINEN, M.S. *see* HEIKKILÄ, J., 299S
NIES, A. *see* CORCELLA, J., 295P
NIES, A.S. *see* MOLINOFF, P.B., 365S
NISELL, H. *see* TOMSON, G., 653
NISKANEN, J. *see* LEHTONEN, A., 445S
NITTER-HAUGE, S. *see* ERIKSSEN, J., 201S
NORLANDER, B. *see* LARSSON, R., 163
NORMAN, T.R. *see* McINTYRE, I.M., 740
NÜESCH, E. *see* HITZENBERGER, G., 217S
NUKADA, T. *see* TAKEDA, T., 49S
NYBERG, L. *see* BOREUS, L.O., 731
NYLUND, L. *see* TOMSON, G., 653

O

O'GRADY, J. *see* KOVACS, I.B., 298P
OHLMEIER, H. *see* GLEICHMANN, U., 301S
OHLSSON, O. Peripheral haemodynamic effects of pindolol, 231S
OHNHAUS, E.E. & TARAS-GERBER, E. Methodological problems in the assessment of platelet aggregation, 265P
OHNHAUS, E.E. *see* PARK, B.K., 737
OLATUNDE, I.A. & PRICE EVANS, D.A. Change in electrocardiographic QT interval produced by quinidine in Britons and Nigerians, 286P

OLIVESI, A. *see* HASSAN, S.M., 605P
OLSEN, H. & MORLAND, J. Ethanol induced increase in procainamide acetylation in man, 203
O'MALLEY, K. *see* DOYLE, V.M., 266P
O'MALLEY, K. *see* DOYLE, V.M., 582P
O'MALLEY, K. *see* DOYLE, V.M., 871
OMEA, T. *see* TAKEDA, T., 49S
OPIE, L.H., WHITE, D. JEE, L. & LUBBE, W.F. Alternatives to β-blockade in therapy of hypertension with angina pectoris: role of nifedipine or labetalol, 115S
OPSTAD, P. *see* ERIKSSEN, J., 201S
ORME, M. *see* BACK, D.J., 280P
ORME, M. *see* BACK, D.J., 325
ORME, M. *see* BRECKENRIDGE, A., 37S
ORME, M.L.E. *see* ADJEPON-YAMOAH, K.K., 829
OROZCO-GONZALEZ, M. *see* WRIGHT, J.M., 847
ORWIN, J.M. *see* CLIFFORD, J.M., 609P
ÖSTERGREN, J. *see* FAGRELL, B., 233S
OTSUKA, K. *see* TSUKIYAMA, H., 269S
OXLEY, J. *see* DHILLON, S., 427

P

PAALZOW, L. *see* TFELT-HANSEN, P., 239
PACHA, W. *see* HITZENBERGER, G., 217S
PACIFICI, G.M. & RANE, A. Distribution of UDP-glucuronyltransferase in different human foetal tissues, 732
PALATINI, P. *see* DAL PALU, C., 97S
PALMER, R.F. *see* McINNES, G.T., 187
PARATI, G. *see* MANCIA, G., 27S
PARIKH, R.K. *see* CAMPBELL, B.C., 604P
PARK, B.K., EICHELBAUM, M. & OHNHAUS, E.E. 6β-Hydroxycortisol excretion in relation to polymorphic *N*-oxidation of sparteine, 737
PARRY, K. *see* DART, A.M., 587P
PASOTTI, C., CAPRA, A., FIORELLA, G., VIBELLI, C. & CHIERICHETTI, S.M. Effects of pindolol and metoprolol on plasma lipids and lipoproteins, 435S
PASQUIER, P. *see* THIBONNIER, M., 533
PASTERNACK, A., PÖRSTI, P. & PÖYHÖNEN, L. Effect of pindolol and propranolol on renal function of patients with hypertension, 241S
PATEL, L. *see* WEERASURIYA, K., 268P
PATON, W.D.M. Hexamethonium, 7
PATTERSON, M., HEAZELWOOD, R., SMITHURST, B. & EADIE, M.J. Plasma protein binding of phenytoin in the aged: *in vivo* studies, 423
PAUDICE, G. *see* CONDORELLI, M., 101S
PAUL, T. *see* DESAI, N.K., 745
PAUL, W. *see* BASRAN, G.S., 607P
PAWAN, G.L.S. & SEMPLE, S.J.G. Effect of oral 3-hydroxybutyrate in obese subjects during therapeutic starvation, 598P
PAYNE, J.P. *see* HUGHES, R., 355
PEARSON, A. *see* SCOTT, P.C., 235
PEART, W.S. The problem of treatment in mild hypertension, 87
PECK, A.W. *see* HAMILTON, M., 411
PECK, A.W. *see* HAMILTON, M., 614P
PECK, A.W. *see* WHITEMAN, P.D., 743
PEDEN, N.R., ISLES, T.E., STEVENSON, I.H. & CROOKS, J. Nadolol in thyrotoxicosis, 835
PEDERSEN, O.L. *see* ANDREASEN, F., 272P
PELTONEN, P. *see* LEHTONEN, A., 445S
PENTLAND, B. *see* CRITCHLEY, J.A.J.H., 276P
PERKINS, R.M. *see* McINNES, G.T., 187
PERKINS, R.M. *see* McINNES, G.T., 331
PERKINS, R.M. *see* McINNES, G.T., 513
PERKINS, R.M. *see* McINNES, G.T., 596P
PERUCCA, E. *see* CHEN, S-S., 547
PESSINI, A.C. *see* DAL PALU, C., 97S
PETERSEN, K.-G. *see* SCHLÜTER, K.J., 407S
PETITCOLAS, J. *see* DUBOIS, D., 375S
PETRIE, J.C. *see* DART, A.M., 587P
PETRIE, J.C. *see* SCOTT, A.K., 289P
PETRIE, J.C. *see* STEELE, W.H., 595P
PIDGEN, A.W. *see* INGS, J.R., 264P
PIDGEN, A.W. *see* LAWRENCE, J.R., 297P
PITCHER, D.W., CURRY, P.V.L. & TROUNCE, J.R. Assessment of β-adrenoceptor blockade in man by prizidilol hydrochloride, 711
PITKETHLY, G.M. *see* WARBURTON, E.M., 600P
PLUMMER, W. *see* KAHN, G.C., 594P
POLAK, G. *see* WRIGHT, J.M., 847
POMIDOSSI, G. *see* MANCIA, G., 27S
PONNIAH, P. *see* ROMAN, E.J., 452
PORTER, E.J.B. *see* BULLINGHAM, R.E.S., 665
PÖRSTI, P. *see* PASTERNAK, A., 241S
PÖYHÖNEN, L. *see* PASTERNAK, A., 241S
PRADALIER, A. *see* DECOURT, S., 567
PRESCOTT, L.F. Assessment of nephrotoxicity, 303
PRESCOTT, L.F. *see* CRITCHLEY, J.A.J.H., 276P
PRICE, M. *see* CLIFFORD, J.M., 609P
PRICE EVANS, D.A. *see* OLATUNDE, I.A., 286P
PRICHARD, B.N.C. Propranolol and β-adrenergic receptor blocking drugs in treatment of hypertension, 51
PRICHARD, B.N.C. & RICHARDS, D.A. Comparison of labetalol with other antihypertensive drugs, 41S
PRICHARD, B.N.C. & WALDEN, R.J. Syndrome associated with withdrawal of β-adrenergic receptor blocking drugs, 337S
PRICHARD, B.N.C. *see* WALDEN, R.J., 359S
PRIESTMAN, D.A. *see* MORELAND, T.A., 647
PROCEEDINGS of a symposium on pindolol: the relevance of intrinsic sympathomimetic activity after 12 years of experience. October 1981, 143S–450S.
PROCEEDINGS of the third symposium on labetalol. June 1981, 1S–141S.
PROCEEDINGS of the British Pharmacological Society, University of London, Imperial College and Institute of Education, 16th–18th December, 1981, 581P–615P.
PROCEEDINGS of the British Pharmacological Society, University of Oxford, 16th–18th September, 1981, 263P–299P.
PUGH, S.E., WHITE, N.J., ARONSON, J.K., GRAHAME-SMITH, D.G. & CARVER, J.G. Erythrocytic digoxin receptor numbers and activity: relation to clinical changes following digoxin withdrawal after longterm treatment for heart failure in sinus rhythm, 271P
PURBA, H.S. *see* BACK, D.J., 325

Q

QUARTERMAN, C.P. *see* KENDALL, M.J., 393

R

RAFTERY, E.B. *see* BOWLES, M.J., 590P
RAFTERY, E.B. *see* DAVIES, A.B., 588P
RAFTERY, E.B. *see* DAVIES, A.B., 705

RAMSAY, L.E. *see* FREESTONE, S., 258
RAMSAY, L.E. *see* FREESTONE, S., 291P
RAMSAY, L.E. *see* McINNES, G.T., 331
RAMSAY, L.E. *see* JACKSON, P.R., 597P
RANE, A. *see* PACIFICI, G.M., 732
RANE, A. *see* STEEN, B., 661
RANE, A. *see* TOMSON, G., 653
RANGNO, R.E. & SERGE LANGLOIS, S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol, 345S
RAPTIS, S. Effects of cardioselective and non-selective β-adrenoceptor blockade on glycogenolysis, lipolysis and growth hormone secretion, 419S
RAWLINS, M.D. *see* BLAIN, P.G., 594P
RAWLINS, M.D. *see* CHAPMAN, P.H., 593P
RAWLINS, M.D. *see* MUCKLOW, J.C., 481
RAWLINS, M.D. *see* SEYMOUR, R.A., 275P
RAWLINS, M.D. *see* SEYMOUR, R.A., 807
RAWLINS, M.D. *see* WILLIAMS, F.W., 595P
RAYMOND, K. *see* McNEIL, J.J., 75S
REDDEL, H.K. *see* BUTCHER, M.A., 241
REDELL, H.K. *see* MARLIN, G.E., 445
REID, J.L. *see* CAMPBELL, B.C., 213
REID, J.L. *see* CAMPBELL, B.C., 291P
REID, J.L. *see* CAMPBELL, B.C., 604P
REID, J.L. *see* CAMPBELL, B.C., 754
REID, J.L. *see* ELLIOTT, H.L., 699
REID, J.L. *see* RUBIN, P.C., 290P
REID, J.L. *see* SCOTT, P.C., 235
REID, J.L. *see* SCOTT, P.J.W., 237
RENWICK, C.F. *see* WALLER, D.G., 577
RICHARDS, D.A. *see* PRICHARD, B.N.C., 41S
RICHENS, A. *see* CHEN, S-S., 547
RICHENS, A. *see* DHILLON, S., 427
RICHENS, A. *see* DHILLON, S., 553
RIEBAND, H.-CH. *see* SCHLÜTER, K.J., 407S
RIECHELMANN, H. *see* RIECKERT, H., 227S
RIECKERT, H., KATTWINKEL, W., RIECHELMANN, H., KUSS, A. & SIERAU, R. Peripheral haemodynamic effects of β-adrenoceptor blocking drugs with ISA or relative β_1-selectivity at rest and during physical exercise, 227S
RIESEN, W. *see* WEIDMANN, P., 449S
RIETBROCK, N. *see* WOODCOCK, B.G., 240
ROBERTS, C.J.C. *see* DANESHMEND, T.K., 817
ROBERTS, C.J.C. *see* ENE, M.D., 298P
ROBERTS, D.F. *see* BLAIN, P.G., 594P
ROBERTS, D.F. *see* MUCKLOW, J.C., 481
ROBINSON, D.S. *see* CORCELLA, J., 295P
ROBERTSON, J.I.S. Labetalol: the nineteen-eighties, 137S
ROBERTSON, J.I.S. *see* ATKINSON, A.B., 855
ROBERTSON, J.I.S. *see* CUMMING, A.M.M., 93S
ROBERTSON, J.I.S. *see* SONKODI, S., 341
ROBINSON, J.D. *see* INGS, R.M.J., 264P
ROBINSON, J.D. *see* LAWRENCE, J.R., 297P
ROBINSON, J.M. The lower urinary tract, 761
ROGERS, H.J. *see* BRADBROOK, I.D., 177
ROGERS, H.J. *see* VANDENBURG, M.J., 747
ROMAN, E.J., PONNIAH, P., LAMBERT, J.B. & BUCHANAN, N. Free sodium valproate monitoring, 452
ROMANELLI, G. *see* AGABITI-ROSEI, E., 87S
ROSANKIEWICZ, J.R. *see* HUSEMEYER, R.P., 171
ROSE, G. Bias, 157
ROSENFELD, J., BONER, G. & WAINER, E. Renal function during acute and long term pindolol treatment in hypertensive patients with normal and decreased glomerular filtration, 237S
ROSKAMM, H. *see* SAMEK, L., 297S
ROSS, D. *see* RUBIN, P.C., 235
ROSSI, G.P. *see* DAL PALU, 97S
ROTH, S. *see* KIRSTEN, R., 397S
ROULSTON, J. *see* MACGREGOR, G.A., 859
ROUTLEDGE, P.A. *see* BARCHOWSKY, A., 411
ROUX, A. *see* THIBONNIER, M., 533
ROWE, P.H. *see* BACK, D.J., 325
ROWELL, F.J. *see* SEYMOUR, R.A., 275P
ROWLAND, E. *see* FLANAGAN, E., 281P
RUBIN, P.C., McLEAN, K. & REID, J.L. Opioids and blood pressure control in man, 290P
RUBIN, P.C., SCOTT, P.J.W., McLEAN, K., PEARSON, A., ROSS, D. & REID, J.L. Atenolol disposition in young and elderly subjects, 235
RUDGE, S.R., LLOYD-JONES, J.K. & HIND, I.D. Interaction between flurbiprofen and indomethacin in rheumatoid arthritis, 448
RUFFIN, R.E., McINTYRE, E.L.M., LATIMER, K.M., WARD, H.E., CROCKETT, A.H. & ALPERS, J.H. Assessment of β-adrenoceptor antagonists in asthmatic patients, 325S
RUSSELL, G.I. *see* HEAGERTY, A.M., 539
RUTLAND, J., GRIFFIN, W. & COLE, P.J. Model for studying effects of pharmacological agents on human ciliary beat frequency: effects of lignocaine, 679
RYLANCE, G.W. *see* FORSYTH, J.S., 811
RYLANCE, G.W. *see* MORELAND, T.A., 647

S

SADLER, M. *see* CHAPUT DE SAINTONGE, D.M., 599P
SALAKO, L.A. *see* ADELUSI, S.A., 451
SALEM, S.A.M., KINNEY, C.D. & McDEVITT, D.G. Pharmacokinetics and psychomotor effects of nitrazepam and temazepam in healthy elderly males and females, 601P
SALHADIN, P., BRAN, M., DE MARNEFFE, M. & DENOLIN, H. Management of patients with chronic atrial fibrillation, 295S
SAMEK, L. & ROSKAMM, H. Antianginal and antiarrhythmic effects of pindolol in post-infarct patients, 297S
SANKEY, M.G., HOLD, J.E. & KAYE, C.M. A simple and sensitive H.P.L.C. method for the assay of prochlorperazine in plasma, 578
SANKEY, M.G. *see* HOLT, J.E., 282P
SASAKI, T. *see* HORAI, Y., 361
SASAKI, T. *see* TSUJIMOTO, G., 493
SAVAGE, I.T. *see* CHAPUT DE SAINTONGE, D.M., 599P
SCARPIGNATO, C., BERTACCINI, G., ZIMBARO, G. & VITULO, F. Ranitidine delays gastric emptying of solids in man, 252
SCHALEKAMP, M.A.D.H. *see* MAN IN'T VELD, A.J., 245S
SCHALEKAMP, M.A.D.H. *see* MAN IN'T VELD, A.J., 367S
SCHALEKAMP, M.A.D.H. *see* VINCENT, H.H., 717
SCHIESS, W. *see* SZÉCSI, E., 353S
SCHIFFL, H. *see* WEIDMANN, P., 449S
SCHLÜTER, K.J., AELLIG, W.H., PETERSEN, K.-G., RIEBAND, H.-CH., WEHRLI, A. & KERP, L. The in-

fluence of β-adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia, 407S
SCHNEIDER, H.H. *see* DOROW, R.G., 561
SCOTT, A.K. & PETRIE, J.C. Assessment of Remler blood pressure recording system, 289P
SCOTT, A.K. *see* DART, A.M., 587P
SCOTT, D.B. Use of labetalol in anaesthesia, 133S
SCOTT, P.J.W. & REID, J.L. The effect of age on the responses of human isolated arteries to noradrenaline, 237
SCOTT, P.J.W. *see* RUBIN, P.C., 235
SCRIVEN, A.J.I., DOLLERY, C.T., BROWN, M.J., MACQUIN, I., MURPHY, M.B. & CAUSON, R.C. Changes in blood pressure and plasma noradrenaline with infusions of tyramine and noradrenaline in normal subjects, 583P
SCRIVEN, A.J. *see* MURPHY, M.B., 608P
SEIDEMAN, P., GRAHNEN, A., HAGLUND, K., LINDSTROM, B. & VON BAHR, C. Prazosin first dose phenomenon during combined treatment with a β-adrenoceptor blocker in hypertensive patients, 865
SEIDLER, J. *see* DOROW, R.G., 561
SELLERS, E.M. *see* NARANJO, C.A., 575
SELLMAN, R. *see* KANTO, J., 736
SEMPLE, S.J.G. *see* PAWAN, G.L.S., 598P
SEMPLICINI, A. *see* DAL PALU, C., 97S
SERLIN, M.J. *see* BRECKENRIDGE, A., 37S
SEWNAUTH, D. *see* CAMPBELL, B.C., 604P
SEYMOUR, R.A. & RAWLINS, M.D. Efficacy and pharmacokinetics of aspirin in postoperative dental pain, 807
SEYMOUR, R.A., ROWELL, F.J. & RAWLINS, M.D. Intravenous dihydrocodeine in post-operative dental pain, 275P
SHAND, D.G. *see* BARCHOWSKY, A., 411
SHANKS, R.G. *see* HARRON, D.W.G., 821
SHARP, J. *see* CHAPUT DE SAINTONGE, D.M., 599P
SHELTON, J.R. *see* McINNES, G.T., 187
SHELTON, J.R. *see* McINNES, G.T., 331
SHELTON, J.R. *see* McINNES, G.T., 513
SHELTON, J.R. *see* McINNES, G.T., 596P
SHEPHERD, A.N. *see* CAMPBELL, B.C., 213
SHEPHERD, A.N. *see* CAMPBELL, B.C., 291P
SHEPHERD, A.N. *see* CAMPBELL, B.C., 754
SHEPHERD, G.L. *see* BLAIR, I.A., 581P
SHEPHERD, G.L. *see* DOWNING, I., 195
SHETH, U.K. *see* DESAI, N.K., 745
SHIGIYA, R. *see* TAKEDA, T., 49S
SHORT, A.H. *see* HERBERT, M., 294P
SIERAU, R. *see* RIECKERT, H., 227S
SILAS, J.H. *see* FREESTONE, S., 291P
SILKE, B. Relationship between plasma β-adrenoceptor blocker concentration and pharmacodynamic activity, 256
SILKE, B. & TAYLOR, S.H. Relationship of plasma concentration of oxprenolol to inhibition of isoprenaline and maximum exercise tachycardia, 587P
SILKE, B. *see* AHUJA, R., 610P
SILKE, B. *see* NELSON, G.I.C., 589P
SILKE, B. *see* TAYLOR, S.H., 590P
SIMON, B. *see* DAMMANN, H.G., 456
SIMPSON, F.O. *see* WAAL-MANNING, H.J., 65S
SINKFIELD, A.W. *see* FAGAN, T.C., 405
SIROIS, G. *see* SPENARD, J., 752
SIVERTSSON, R. *see* SVENSSON, A., 259S
SJOERDSMA, A. Methyldopa, 45
SKEWS, H. *see* LITTLE, P.J., 785
SLACK, R. *see* GREENWOOD, D., 619
SLOAN, T.P. *see* KONG, I., 275P
SMITH, C.L. *see* WALLER, D.G., 577
SMITH, P. *see* HAMILTON, M., 614P
SMITH, P. *see* WHITEMAN, P.D., 743
SMITH, R.L. *see* KONG, I., 275P
SMITHURST, B. *see* PATTERSON, M., 423
SOEP, H.H. *see* THOMIS, J.A., 260
SOMERVILLE, K. *see* BELL, G.D., 278P
SOOD, V.P. *see* SONKODI, S., 341
SONKODI, S., AGABITI-ROSEI, E., FRASER, R., LECKIE, B.J., MORTON, J.J., CUMMING, A.M.M., SOOD, V.P. & ROBERTSON, J.I.S. Response of the renin-angiotensin-aldosterone system to upright tilting and to intravenous frusemide: effect of prior metoprolol and propranolol, 341
SPECTOR, R.G. *see* BRADBROOK, I.D., 177
SPENARD, J., SIROIS, G. & GAGNON, M.A. Second peak in serum levels curve after oral administration of slow-release quinidine dosage form: effect of food, 752
SPENCER, K.M. *see* GIBBERD, F.B., 455
SPENCER, M. *see* BORLAND, R.G., 272P
SPERTI, G. *see* DAL PALU, C., 97S
SPITZER, D. *see* FITSCHA, P., 211S
STAIGER, C. *see* BACK, D.J., 280P
STANDEN, P.J. *see* HERBERT, M., 294P
STARGEL, W.W. *see* BARCHOWSKY, A., 411
STARK, R.D. & GAMBLES, S.A. Does diazepam reduce breathlessness in healthy subjects, 600P
STEELE, W.H., BARBER, H.E., DAWSON, A.A., KING, D.J. & PETRIE, J.C. Protein binding of prednisolone and vinblastine in the serum of normal subjects, 595P
STEELE, W.H. *see* BRYSON, S.M., 287P
STEEN, B. & RANE, A. Clindamycin passage into human milk, 661
STEINESS, E. *see* SVENDSEN, T.L., 223S
STEVENS, A.J. *see* HOLMES, J., 274P
STEVENSON, I.H. *see* PEDEN, N.R., 835
STEWART, A.G. *see* GRIFFIN, J.P., 253
STEWART, I. McD.G. β-Adrenoceptor blockade and the incidence of myocardial infarction during treatment of severe hypertension, 91
STIEHL, A. *see* GUNDERT-REMY, U., 795
STOCKER, K. *see* LOHMÖLLER, G., 315S
STONE, B.M. *see* BORLAND, R.G., 272P
STONE, B.M. *see* NICHOLSON, A.N., 199
STONE, B.M. *see* NICHOLSON, A.N., 433
STONE, B.M. *see* NICHOLSON, A.N., 603P
STOREY, G.C.A. *see* FLANAGAN, R.J., 281P
STRANDBERG, T. *see* MIETTINEN, T.A., 431S
STRAUER, B.E. *see* HAHN, B., 305S
STROCCHI, E. *see* MALINI, P.L., 123S
STRUTHERS, A.D. *see* WHITING, B., 610P
SUBRAMANIAN, V.B. *see* BOWLES, M.J., 590P
SUBRAMANIAN, V.B. *see* DAVIES, A.B., 588P
SUBRAMANIAN, V.B. *see* DAVIES, A.B., 705
SUGANUMA, T. *see* TSUJIMOTO, G., 493
SUKERMAN-VOLDMAN, E. Pindolol therapy in pregnant hypertensive patients, 379S
SUMNER, D.J. *see* BRYSON, S.M., 287P
SUMNER, D.J. *see* ELLIOTT, H.L., 699
SUMNER, D.J. *see* WHITING, B., 529
SVENDSEN, T.L., TANGØ, M., WALDORFF, S., STEINESS,

E. & TRAP-JENSEN, J. Effects of propranolol and pindolol on plasma lignocaine clearance in man, 223S
SVENDSEN, T.L. *see* TRAP-JENSEN, J., 391S
SVENSSON, A., GUDBRANDSSON, T., SIVERTSSON, R. & HANSSON, L. Haemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients, 259S
SWALES, J.D. *see* HEAGERTY, G.I., 539
SZABADI, E. *see* MAPLE, S., 584P
SZÉCSI, E., KOHLSCHÜTTER, S., SCHIESS, W. & LANG, E. Abrupt withdrawal of pindolol or metoprolol after chronic therapy, 353S

T

TAKEDA, T., KANEKO, Y., OMEA, T., YOSHINAGA, K., MUSUYAMA, Y., NUKADA, T. & SHIGIYA, R. Use of labetalol in Japan, results of multicentre clinical trials, 49S
TANGÓ, M. *see* SVENDSEN, T.L., 223S
TANGÓ, M. *see* TRAP-JENSEN, J., 391S
TARAS-GERBER, E. *see* OHNHAUS, E.E., 265P
TAUCHERT, M. *see* HOMBACH, V., 285S
TAYLOR, D.R., KINNEY, C.D. & McDEVITT, D.G. Plasma theophylline concentrations in patients with chronic obstructive airways disease after administration of a new sustained release theophylline formulation, 569
TAYLOR, I. *see* BACK, D.J., 325
TAYLOR, S.H., SILKE, B. & NELSON, G.I.C. The haemodynamic effects of drugs with combined positive inotropic and vasodilator activity on the failing heart in man, 590P
TAYLOR, S.H. *see* AJUJA, R., 610P
TAYLOR, S.H. *see* NELSON, G.I.C., 589P
TAYLOR, S.H. *see* SILKE, B., 587P
TEMPERVILLE, B. *see* DUBOIS, D., 375S
TEMPLE, D.J. *see* McELNAY, J.C., 399
TETSCH, P. *see* BRISSE, B., 421S
TFELT-HANSEN, P., PAALZOW, L. & IBRAHEEM, J.J. Bioavailability of sublingual ergotamine, 239
THALME, B. *see* TOMSON, G., 653
THAULOW, E. *see* ERIKSSEN, J., 201S
THEIN, TH. *see* HOUBEN, H., 259
THIBONNIER, M., FLABEAU, C., THOUVENIN, M., ROUX, A., FLOUVAT, B., PASQUIER, P.& MENARD, J. Antihypertensive effect of diacetolol in essential hypertension, 533
THOMAS, E. *see* BACK, D.J., 280P
THOMIS, J.A., SOEP, H.H., HALLYNK, T., BOELAERT, J., DANEELS, R. & DETTLI, L. Creatinine clearance, different methods of determination, 260
THOMPSON, P.J. *see* MARLIN, G.E., 445
THOUVENIN, M. *see* THIBONNIER, M., 533
THULESIUS, O., GJÖRES, J.E. & BERLIN, E. Vasodilating properties of β-adrenoceptor-blockers with intrinsic sympathomimetic activity, 229S
THURSTON, H. *see* HEAGERTY, A.M., 539
TIMMIS, A.D., FOWLER, M.B., JAGGARAO, N.S.V., VINCENT, R. & CHAMBERLAIN, D.A. Role of labetalol in acute myocardial infarction, 111S
TISO, B. *see* FITSCHA, P., 211S
TJIA, J. *see* BACK, D.J., 280P
TOMLINSON, B. *see* WALDEN, R.J., 359S
TOMSON, G., ING, R., GARLE, M., THALME, B., NISELL, N., NYLUND, L. & RANE, A. Maternal kinetics and transplacental passage of pethidine during labour, 653
TRAP-JENSEN, J., CARLSEN, J.E., HARTLING, O.J., SVENDSEN, T.L., TANGÓ, M. & CHRISTENSEN, N.J. β-Adrenoceptor blockade and psychic stress in man. A comparison of the acute effects of labetalol, metoprolol, pindolol and propranolol on plasma levels of adrenaline and noradrenaline, 391S
TRAP-JENSEN, J. *see* SVENDSEN, T.L., 223S
TRIEB, G. *see* GLEICHMANN, U., 301S
TROUNCE, J.R. *see* PITCHER, D.W., 711
TRUELOVE, S.C. *see* KHAN, A.K.A., 523
TSUJIMOTO, G., SASAKI, T., ISHIZAKI, T., SUGANUMA, T. & HIRAYAMA, H. Re-examination of digoxin dosage regimen: comparison of the proposed nomograms or formulae in elderly patients, 493
TSUKIYAMA, H., OTSUKA, K. & HIGUMA, K. Effects of β-adrenoceptor antagonists on central haemodynamics in essential hypertension, 269S
TUCKER, G.T. *see* JACKSON, P.R., 263P
TURNER, P. *see* CULIG, J., 243
TURNER, P. *see* HONG, C.Y., 285P
TWEDDEL, A.C., BEATTIE, J.M., MURRAY, R.G. & HUTTON, I. Are propranolol and nifedipine synergistic in angina pectoris—a reply, 256

U

UPRICHARD, G. *see* McELNAY, J.C., 501

V

VALETTE, H., APOIL, E. & HILPERT, F. Effects of heating on haemodynamic action of glyceryl trinitrate, 250
VAN BOXTEL, C.J. *see* DANHOF, M., 379
VAN DER GRAAFF, M. *see* JOCHEMSEN, R., 319
VAN 'T LAAR, A. *see* HOUBEN, H., 259
VANDENBURG, M.J., WRIGHT, P., HOLMES, J., ROGERS, H.J. & AHMAD, R.A. Hypotensive response to hydralazine in triple therapy is not related to acetylator phenotype, 747
VANHANEN, H. *see* MIETTINEN, T.A., 431S
VENNING, G.R. *see* McINNES, G.T., 331
VERBEEK, R.M.A. *see* DANHOF, M., 379
VERE, D.W. *see* CHAPUT DE SAINTONGE, D.M., 155
VERE, D.W. *see* CHAPUT DE SAINTONGE, D.M., 775
VERE, D.W. *see* HOLMES, J., 274P
VERRIENTI, S. *see* CONDORELLI, M., 101S
VIBELLI, C. *see* PASOTTI, C., 435S
VINCENT, H.H., MAN IN'T VELD, A.J., BOOMSMA, F., WENTING, G.J. & SCHALEKAMP, M.A.D.H. Elevated plasma noradrenaline in response to β-adrenoceptor stimulation in man, 717
VINCENT, R. *see* TIMMIS, A.D., 111S

VITULO, F. *see* SCARPIGNATO, C., 252
VON BAHR, C. *see* SEIDEMAN, P., 865

W

WAAL-MANNING, H.J. & SIMPSON, F.O. Review of long-term treatment with labetalol, 65S
WAGNER, G.S. *see* BARCHOWSKY, A., 411
WAINER, E. *see* ROSENFELD, J., 237S
WAITE, R. *see* WEIL, C., 279S
WAKEFIELD, V. *see* JACKSON, P.R., 597P
WALAN, A. *see* LARSSON, R., 163
WALDEN, R.J., BHATTACHARJEE, P., TOMLINSON, B., CASHIN, J., GRAHAM, B.R. & PRICHARD, B.N.C. The effect of intrinsic sympathomimetic activity on β-receptor responsiveness after β-adrenoceptor blockade withdrawal, 359S
WALDEN, R.J. *see* PRICHARD, B.N.C., 337S
WALDORFF, S. *see* SVENDSEN, T.L., 223S
WALLE, T. *see* FAGAN, T.C., 511
WALLE, U.K. *see* FAGAN, T.C., 511
WALLER, D.G., SMITH, C.L. & RENWICK, C.F. Intravenous propranolol in patients with inflammation, 577
WANG, C., LAI, C.L., LAM, K.C. & YEUNG, K.K. Effect of cimetidine on gonadal function in man, 791
WARBURTON, D.M., WESNES, K. & PITKETHLY, G.M. Residual effects of temazepam and flurazepam on attentional performance, 600P
WARD, H.E. *see* RUFFIN, R.E., 325S
WARD, S.A. *see* ADJEPON-YAMOAH, K.K., 829
WARDLEWORTH, A.G. *see* MARLOW, H.F., 269P
WARRINGTON, S.J. *see* WEERASURIYA, K., 268P
WEBER, E. *see* GUNDERT-REMY, U., 795
WEBLEY, M. *see* GIBBERD, F.B., 455
WEERASURIYA, K., WARRINGTON, S.J. & PATEL, L. Detection of partial agonist activity of pindolol using systolic time intervals, 268P
WEHRLI, A. *see* SCHLÜTER, K.J., 407S
WEIDMANN, P., SCHIFFL, H., BIEHRINGER, K., MEIER, A., MORDASINI, R. & RIESEN, W. Effects of diuretics alone or in combination with β-adrenoceptor blockers on serum lipoproteins, 449S
WEIL, C. & WAITE, R. Haemodynamic differences in untreated hypertension and hypertension treated with various β-adrenoceptor antagonists, 279S
WELZEL, D. *see* KIRSTEN, R., 397S
WENTING, G.J. *see* VINCENT, H.H., 717
WESNES, K. *see* WARBURTON, D.M., 600P
WHITE, N.J. *see* ARONSON, J.K., 606P
WHITE, D. *see* OPIE, L.H., 115S
WHITE, D.A. *see* BELL, G.D., 278P
WHITE, N.J. *see* PUGH, S.E., 271P
WHITEMAN, P.D., PECK, A.W., FOWLE, A.S.E. & SMITH, P. Bupropion fails to affect plasma prolactin and growth hormone in normal subjects, 743
WHITING, B., KELMAN, A.W. & STRUTHERS, A.D. Variability in bronchodilator response to theophylline in chronic bronchitis, 610P
WHITING, B., KELMAN, A.W., SUMNER, D.J., HILLIS, W.S. & LEDERMANN, H. Haemodynamic effects of BM 10.188, a new orally active inotropic agent, in healthy volunteers, 529
WHITING, B. *see* BRYSON, S.M., 417
WHITMARSH, V.B. *see* BENNETT, P.N., 387
WHITTINGHAM, T.A. *see* BATEMAN, D.N., 675
WHITTINGTON, J.R. *see* HURLOW, R.A., 803
WILD, R.N. *see* MAUDGAL, D.P., 279P
WILCOX, R.G. & HAMPTON, J.R. Comparison between atenolol and nadolol in essential hypertension at rest and on exercise, 841
WILKINSON, G.R. *see* FEELY, J., 591P
WILLIAMS, F.M., WOODHOUSE, K.W., JAMES, O.F.W., MIDDLETON, D., WRIGHT, P. & RAWLINS, M.D. Aldrin epoxidation by human liver microsomes, 595P
WILLIAMS, N.E. *see* CALVEY, T.N., 293P
WILLIAMS, N.E. *see* ISHERWOOD, C.N., 612P
WOLFE, B.B. *see* MOLINOFF, P.B., 365S
WOODHOUSE, K.W. & HENDERSON, D.B. High pressure liquid chromatographic method for the determination of melphalan in plasma, 605P
WOODHOUSE, K.W. *see* WILLIAMS, F.M., 595P
WOOD, A.J., FERRY, D.G. & BAILEY, R.R. Elimination kinetics of labetalol in severe renal failure, 81S
WOOD, A.J.J. *see* FEELY, J., 591P
WOOD, A.J.J. *see* FEELY, J., 592P
WOOD, P. *see* BLAIN, P.G., 594P
WOODCOCK, B.G. & RIETBROCK, N. Verapamil bioavailability and dosage in liver disease, 240
WOODS, H.F. *see* JACKSON, P.R., 263P
WOODS, K.L. *see* KENDALL, M.J., 393
WRIGHT, J.M., OROZCO-GONZALEZ, M., POLAK, G. & DOLLERY, C.T. Duration of effect of single daily dose methyldopa therapy, 847
WRIGHT, P. *see* VANDENBURG, M.J., 747
WRIGHT, P. *see* WILLIAMS, F.W., 595P

Y

YEUNG, K.K. *see* WANG, C., 791
YOSHINAGA, K. *see* TAKEDA, T., 49S

Z

ZAAGSMA, J. *see* HARMS, H.H., 181S
ZAMAN, R., KENDALL, M.J. & BIGGS, P.I. The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide, 507
ZIMBARO, G. *see* SCARPIGNATO, C., 252

SUBJECT INDEX

A

Acebutolol, comparison of effects of propranolol, pindolol, oxprenolol, and, on atrioventricular conduction in unanaesthetised dogs, 159S

—, effect of, and propranolol on hypoglycaemic action of glibenclamide, 507

Acetylation phenotypes, a simple pharmacokinetic method for separating the three, 375

Acetylator, hypotensive response to hydralazine in triple therapy is not related to phenotype, 747

Adenylate cyclase, lymphocyte, activity and sodium fluoride sensitivity in relation to age, 582P

—, prostacyclin binding and activation of, in normal and diabetic platelets, 581P

—, sodium fluoride activation of human lymphocyte, is reduced in old age, 871

α-Adrenoceptor antagonist, assessment of a new, doxazosin (UK33274) in normotensive subjects, 699

α-Adrenoceptor blockade, effects of combined, and β-blockade by labetalol in patients with coronary heart disease, 101S

—, the place of, and β-adrenoceptor blockade in treatment of hypertension, 5S

α_2-Adrenoceptor antagonist, reversal of some effects of clonidine by RX 78,1094, 609P

β-Adrenoceptor, effects of pindolol and propranolol, on human lymphocytes, 365S

—, propranolol and, blocking drugs in the treatment of hypertension, 49

β-Adrenoceptor agonist, effects of, and antagonists in patients with peripheral autonomic neuropathy, 367S

—, effects of, and antagonists on a mediator induced wheal response in human skin, 607P

—, haemodynamic effects of oral doses of ICI 118,587, in healthy volunteers, 269P

β-Adrenoceptor antagonist, assessment of, in asthmatic patients, 325S

—, effect of, pindolol on exercise performance, 723

—, effects of, on central haemodynamics in essential hypertension, 268S

—, haemodynamic differences in untreated hypertension and hypertension treated with various, 279S

—, influence of, with and without ISA on local wall motion abnormalities in patients with coronary heart disease, 301S

—, radio-receptor assay for, using solubilized receptor protein, 284P

—, treatment of hypertension in pregnancy with, 375S

β-Adrenoceptor blockade, and atrioventricular conduction in dogs, role of intrinsic sympathomimetic activity, 167S

—, and psychic stress in man, 391S

—, and the incidence of myocardial infarction during treatment of severe hypertension, 89

—, assessment of, in man by prizidilol hydrochloride, 711

—, effect of ISA on β-receptor responsiveness after, withdrawal, 359S

—, effects of cardioselective and non-selective on glycogenesis, lipolysis and growth hormone secretion, 419S

—, effects of combined α-blockade and, by labetalol in patients with coronary heart disease, 101S

—, effects of, on carbohydrate metabolism during exercise—comparison of pindolol and metoprolol, 429S

—, haemodynamic effects of cigarette smoking during, 258

—, influence of, on left ventricular function, 305S

—, in stress due to oral surgery, 421S

—, relationship of plasma catecholamines to blood pressure in hypertensive patients during, with and without ISA, 397S

—, the place of α-adrenoceptor blockade and, in treatment of hypertension, 5S

β-Adrenoceptor blocker, and lipolysis, 181S

—, antihypertensive action of acebutolol (sectral) when used concomitantly with hydrochlorothiazide, 209

—, comparison of pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros® delivery system, 393

—, comparison of, under maximal exercise (pindolol v metoprolol v atenolol), 201S

—, effects in man of ICI 118551 on some cardiovascular responses induced by isoprenaline, 586P

—, effects of diuretics alone or in combination with, on serum lipoproteins, 449S

—, electrophysiological effects of cardioselective and non-cardioselective, with and without ISA, 285S

—, experiments with bopindolol (LT 31-200): a long acting, with partial agonist activity, 267P

—, HDL cholesterol and, in a 5 year multifactorial primary prevention trial, 431S

—, influence of intrinsic sympathomimetic activity of, on heart rate and blood pressure responses to graded exercise, 257

—, influence of, on lymphocyte function *in vitro*, 543

—, influence of, with and without ISA on hormonal responses to hypo- and hyperglycaemia, 407S

—, interpretation of isoprenaline dose response curves in presence of selective and non-selective, 585P

—, peripheral haemodynamic effects of, with ISA or β_1-selectivity at rest and during exercise, 227S

—, pindolol—a, with partial agonist activity: clinical pharmacological considerations, 187S

—, prazosin first dose phenomenon during combined treatment with a, in hypertensive patients, 865

—, relationship between plasma, concentration and pharmacodynamic activity, 256

—, relevance of ISA, 317S

—, relevance of selectivity and non-selectivity in, 199S

—, syndrome associated with withdrawal of, 337S

—, vasodilating properties of, with ISA, 229S

β-Adrenoceptor blocking activity, comparison of, measured by radio-receptor assay and physiological cardiac β-adrenoceptor blockade, 613P

β-Adrenoceptor stimulation, elevated plasma noradrenaline in response to, in man, 717

Adverse drug reaction, comparison of two recently published algorithms for assessing the probability of, 223

Age, effects of, and smoking on pharmacokinetics of pindolol and propranolol, 217S

—, influence of, on pharmacokinetics of midazolam, 602P

—, lymphocyte adenylate cyclase activity and sodium fluoride sensitivity in relation to, 582P

—, sodium fluoride activation of human lymphocyte adenylate cyclase is reduced in old, 871

Aldosterone antagonist, relative potency and structure activity relationships of, in healthy man: correlation with animal experience, 331
Aldrin epoxidation, by human liver microsomes, 595P
Alinidine, pharmacokinetics following acute and chronic dosing, 821
Aluminium hydroxide gel, use of buccal partitioning as a model to examine the effects of, on the absorption of propranolol, 399
Amiodarone, h.p.l.c. measurement of, and its desethyl metabolite in plasma, 281P
Amitriptyline, effects of phenelzine or, on plasma free tryptophan during treatment of depression, 295P
Amoxycillin, comparison of plasma and bile concentrations of, and ceftriaxone after bolus intravenous administration, 279P
Ampicillin, interaction between, and oral contraceptive steroids in women, 280P
Anaemia, prolongation of antipyrine half-life after correction of severe, due to hookworm infestation, 745
Anaesthesia, comparison of fentanyl and halothane supplementation to general, on stress response in abdominal surgery, 604P
—, use of labetalol in, 133S
Analgesia, a study of pethidine kinetics and, in women in labour following intravenous, intramuscular and epidural administration, 171
Angina, antianginal and antiarrhythmic effects of pindolol in post-infarct patients, 297S
—, effect of pindolol and myocardial release of inosine hypoxanthine and lactate during pacing-induced, 313S
—, efficacy of new calcium channel blocking agent, nicardipine, in chronic stable, 590P
Angina pectoris, alternatives to β-blockade in therapy of hypertension with angina pectoris: role of nifedipine or labetalol, 115S
—, are propranolol and nifedipine synergistic in, 255
Angiotensin converting enzyme inhibitor, effects of, captopril in essential hypertension, 213
—, prolonged, inhibition by captopril in patients with renal failure, 291P
Anticholinergic effects, procyclidine, and atropine: comparison of, in man, 614P
Antihypertensive drugs, and blood lipids: the Oslo study, 441S
—, comparison of labetalol with other, 41S
—, sample size for short-term trials of, 292P
Antihypertensive effect, of diacetolol in essential hypertension, 533
Antipyrine, and paracetamol metabolism in obstructive jaundice, 277P
—, effect of rifampicin on metoprolol and, kinetics, 387
—, elimination in saliva after low-dose combined or progestogen-only contraceptive steroids, 229
—, prolongation of, half-life after correction of severe anaemia due to hookworm infestation, 745
Antipyrine kinetics, short term effects of propranolol, atenolol, and labetalol on, in normal subjects, 817
Antipyrine metabolism, effect of fever on, in children, 811
—, relationship between individual dietary constituents and, in Indo-Pakistani immigrants, 481
Antipyrine metabolite, differential effects of enzyme induction on, formation, 379
Anxiety, responsiveness of sweat glands to phenylephrine and carbachol in, neurosis, 584P
Aspirin, efficacy and pharmacokinetics of, in postoperative dental pain, 807
—, protein binding of chloroquine in the presence of, 451
Astemizole, performance studies with the H_1-histamine receptor antagonists, and terfenadine, 199
—, randomized single-blind study of, and chlorpheniramine in normal volunteers, 593P
Asthma, assessment of β-adrenoceptor antagonists in asthmatic patients, 325S
—, influence of ISA during β-adrenoceptor blockade in asthmatics, 321S
Atenolol, comparison between, and nadolol in essential hypertension at rest and on exercise, 841
—, disposition in young and elderly subjects, 235
—, short term effects of propranolol, and labetalol on antipyrine kinetics in normal subjects, 817
Atrial fibrillation, management of patients with chronic, 295S
Atrioventricular conduction, β-adrenoceptor blockade and, in dogs, role of sympathomimetic activity, 167S
—, comparison of effects of propranolol, pindolol, oxprenolol and acebutolol on, in unanaesthetised dogs, 159S
Atropine, heart rate and blood pressure responses to intravenous boluses of isoprenaline before and after, 266P
Autoimmune disease, incidence of hydrallazine-associated, 291P

B

Benzodiazepine, a radioreceptor assay to study affinity of, and their receptor binding activity in human plasma, 561
Bethanidine, the discovery of bretylium and, 23
Blood cell velocity, effect of intravenously administered pindolol on skin capillary, in fingers, 233S
Blood pressure, assessment of Remler, recording system, 289P
—, opioids and, in man, 290P
—, rapid reduction of, with acute administration of oral labetalol, 588P
—, rapid reduction of, with acute oral labetalol, 705
—, relationship of plasma catecholamines to, in hypertensive patients during β-adrenoceptor blockade with and without ISA, 397S
—, response to labetalol in twice and three times daily administration during a 24-hour period, 27S
BM 10.188, haemodynamic effects of, a new orally active inotropic agent in healthy volunteers, 529
Bopindolol, experiments with, (LT 31-200): a long acting β-adrenoceptor blocker with partial agonist activity, 267P
Bradycardia, can ISA compensate for, due to β-adrenoceptor blockade, 315S
Breast milk, terbutaline excretion into, 729
—, terbutaline in, 731
Bretylium, the discovery of, and bethanidine, 23
Bronchodilator activity, of prazosin in patients with allergic rhinitis and asthma, 445
Bronchodilator response, variability in, to theophylline in chronic bronchitis, 610P
Bufuralol, defective hydroxylation of, associated with side-effects of, in poor metabolisers, 750

Buprenorphine, comparative study of intramuscular, and morphine in treatment of chronic pain of malignant origin, 487
—, sublingual, used postoperatively: ten hour plasma drug concentration analysis, 665
Bupropion, fails to affect plasma prolactin and growth hormone in normal subjects, 743

C

Captopril, effects of, in essential hypertension, 213
—, prolonged angiotensin converting enzyme inhibition by, in patients with renal failure, 291P
—, prolonged converting enzyme inhibition in patients with renal insufficiency, 754
—, treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure, 855
Carbachol, responsiveness of sweat glands to phenylephrine and, in anxiety neurosis, 584P
Carbamazepine, saliva, levels in children before and during multiple dosing, 647
Carbohydrate metabolism, effects of β-adrenoceptor blockade on, during exercise—comparison of pindolol and metoprolol, 429S
Catecholamine, elevated plasma, in young hypertensive and hyperkinetic patients: effect of pindolol, 381S
—, h.p.l.c. determination of plasma, in road accident casualties, 283P
—, relationship of plasma, to blood pressure in hypertensive patients during β-adrenoceptor blockade with and without ISA, 397S
Ceftriaxone, comparison of plasma and bile concentrations of amoxycillin and, after bolus intravenous administration, 279P
Chenodeoxycholic acid, how does Rowachol enhance the cholelitholytic potential of low and medium dose, 278P
Chloroquine, protein binding of, in the presence of aspirin, 451
Chlorothiazide, 15
Chlorpheniramine, randomized single-blind study of astemizole and, in normal volunteers, 593P
Chronic pain, comparative study of intramuscular buprenorphine and morphine in treatment of, of malignant origin, 487
Cholesterol, HDL, and β-adrenoceptor blockers in a 5 year multifactorial primary prevention trial, 431S
Ciliary beat, *in vitro* model for studying effects of pharmacological agents on human, frequency: effects of lignocaine, 679
Cimetidine, effect of long-term, treatment on left ventricular function in haemodialysis patients with active hyperparathyroidism, 693
—, effect of, on gonadal function in man, 791
—, pharmacokinetics of, and its sulphoxide metabolite in patients with normal and impaired renal function, 163
—, reduction in lignocaine clearance by, 591P
Circadian heart rate, effect of intrinsic sympathomimetic activity of β-adrenoceptor blockers on, 211S
Circulation, response of systemic and pulmonary, to labetalol at rest and during exercise, 13S
Circulatory regulation, in hypertension, 93
Clindamycin, passage into human milk, 661
Clinical trials, anticipating numbers of subjects in, 274P
—, bias, 157
—, ethically optimized designs, 469
—, measurement in, 775
—, methods in clinical pharmacology: series, 155
—, randomised controlled trials: sampling, 631
—, six months experience of new procedures affecting the conduct of, in UK, 253
Clobazam, in the treatment of catamenial epilepsy, 273P
Clonidine, reversal of some effects of, by RX 781094, an α_2-adrenoceptor antagonist, 609P
Coronary blood flow, intrinisc sympathomimetic activity and, 175S
Coronary heart disease, effect of pindolol, on myocardial blood flow, metabolism and function during rest and pacing in patients with, 309S
—, haemodynamic dose-response effects of labetalol in, 589P
—, influence of β-adrenoceptor antagonists with and without ISA on local wall motion abnormalities in patients with, 301S
Creatine phosphate, studies of haemodynamic effects of, in man, 803
Creatinine clearance, different methods of determination, 260
Cyclizine, a comparison of triprolidine and, in histamine (H_1) antagonism, subjective effects and performance in man, 441
Cyclopenthiazide, xipamide and, in essential hypertension—comparative effects of blood pressure and plasma potassium, 859

D

Debrisoquine, assay and characterisation of, 4-hydroxylase activity of microsomal fractions of human liver, 637
—, enzymatic basis for defective 4-hydroxylation of, 594P
Decamethonium, tachyphylaxis after repeated dosage of, in anaesthetized man, 355
Dental pain, efficacy and pharmacokinetics of aspirin in postoperative, 807
—, intravenous dihydroeodeine in post-operative, 275P
Depression, effects of phenelzine or amitriptyline on plasma free tryptophan during treatment of depression, 295P
Diabetes mellitus, oxprenolol, methyldopa and lipids in, 219
Diabetic control, evaluation of, in Kenyan black Africans on various treatments using the HBA_{1c}, 615P
Diabetic platelets, prostacyclin binding and activation of adenylate cyclase in normal and, 581P
Diacetolol, antihypertensive effect of, in essential hypertension, 533
Diazepam, bioavailability of, after intravenous, oral and rectal administration in adult epileptic patients, 427
—, does, reduce breathlessness in healthy subjects, 600P
—, valproic acid and, interaction *in vivo*, 553
Diet, relationship between individual, constituents and antipyrine metabolism in Indo-Pakistani immigrants, 481
Diethylcarbamazine, effect of renal disease on pharmacokinetics of, in man, 829
Digoxin, effect of, on *in vivo* disposition of an oral load of rubidium chloride, 606P
—, erythrocytic, receptor numbers and activity, 271P

—, re-examination of, dosage regimen: comparison of proposed nomograms or formulae in elderly patients, 493
Dihydrocodeine, intravenous, in post-operative dental pain, 275P
Dihydroergotamine, bioavailability of, in man, 785
Dimethicone, effect of activated, and a proprietary antacid containing this agent on absorption of phenytoin, 501
Dimethothiazine, sensitive h.p.l.c. assay methods for monitoring methotrimeprazine and, levels in plasma, 282P
Disopyramide, influence of protein binding on, clearance, 287P
—, pharmacokinetics during recovery from myocardial infarction, 417
—, serum protein binding of, 288P
Diuretics, effects of, alone or in combination with β-adrenoceptor blockers on serum lipoproteins, 449S
DL308, psychopharmacological evaluation of, in healthy volunteers, 294P
Domperidone, effects of, on gastric emptying of liquid in man, 675
Doxazosin, assessment of a new α-adrenoceptor antagonist, in normotensive subjects, 699

E

Enzyme induction, differential effects of, on antipyrine metabolite formation, 379
Epilepsy, bioavailability of diazepam after intravenous, oral and rectal administration in adult, 427
—, clobazam in the treatment of catamenial, 273P
—, kinetic interaction of mianserin in, patients on anticonvulsant drugs, 612P
Ergotamine, bioavailability of sublingual, 239
Erythromycin, dose-related pharmacokinetics after oral administration of a new formulation of, base, 685
—, kinetics in patients on haemodialysis, 611P
Ethanol, induced increase in procainamide acetylation in man, 203

F

Fatty acids, unaltered serum propranolol binding by meal-induced variations in, 575
Fentanyl, comparison of, and halothane supplementation to general anaesthesia on stress response in abdominal surgery, 604P
Flecainide, serum protein binding of, 606P
Flecainide acetate, electrophysiological effects of, (R-818) on the cardiac conduction system, 286P
Flunitrazepam, hypnotics with single and multi-compartment model kinetics, 272P
Flurazepam, residual effects of temazepam and, on attentional performance, 600P
Flurbiprofen, interaction between, and indomethacin in rheumatoid arthritis, 448
Foetal tissue, distribution of UDP-glucuronyltransferase in different human, 732
Frusemide, acute non-diuretic vascular responses of, in man, 589P
—, response of renin-angiotensin-aldosterone system to upright tilting and,: effect of prior metoprolol and propranolol, 341

G

Ganglion blocking drugs, the introduction of, for the treatment of hypertension, 61
Gastric emptying, effects of domperidone on, of liquid in man, 675
Gastric secretion, inhibitory effects of SCH 28080 on, in man 298P
Glibenclamide, effect of acebutolol and propranolol on hypoglycaemic action of, 507
—, pharmacokinetics in healthy volunteers: evidence for zero-order drug absorption, 264P
Glucose tolerance, after 14 years of diuretic therapy, 598P
Glyceryl trinitrate, effects of heating on haemodynamic action of, 250
Gonadal function, effect of cimetidine on, in man, 791
Guanethidine, after twenty years: a pharmacologist's perspective, 33
Gut wall, metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans, 325

H

Haemodialysis, erythromycin kinetics in patients on, 611P
Haemodynamic differences, in untreated hypertension and hypertension treated with various β-adrenoceptor antagonists, 279S
Halothane, comparison of fentanyl and, supplementation to general anaesthesia on stress response in abdominal surgery, 604P
Hexamethonium, 7
Histamine receptor blocker, reduction in apparent liver blood flow in man by, and inhibition of prostaglandin synthesis, 592P
H_1-histamine antagonism, comparison of triprolidine and cyclizine on, subjective effects and performance in man, 441
H_1-histamine receptor antagonists, performance studies with the, astemizole and terfenadine, 199
Hoe 766, dose response characteristics of, (Buserelin) following intranasal administration to five healthy male volunteers, 297P
Hydrazine, circulating, during treatment with isoniazid rifampicin in man, 599P
Hydralazine, hypotensive response to, in triple therapy is not related to acetylator phenotype, 747
—, incidence of, associated autoimmune disease, 291P
—, oxprenolol interactions, 587P

Hydrochlorothiazide, antihypertensive action of acebutolol (Sectral) when used concomitantly with, 209
6β-Hydroxycortisol, excretion in relation to polymorphic *N*-oxidation of sparteine, 737
Hyperglycaemia, influence of β-adrenoceptor blockers with and without ISA on hormonal responses to hypoglycaemia and, 407S
Hypertension, a clinician looks at the future, 124
—, addition of prazosin to standard triple therapy on treatment of severe, 539
—, antihypertensive effects of lofexidine in patients with essential hypertension, 405
—, β-adrenoceptor blockade and the treatment of myocardial infarction during treatment of severe, 89
—, can we develop new drugs for, 131
—, chlorothiazide, 13
—, circulatory regulation in, 93
—, comparison between atenolol and nadolol in essential, at rest and on exercise, 841
—, effect of pentolinium on plasma catecholamines in hypertensive and normal controls, 608P
—, effect of propranolol and pindolol on renal function of patients with, 241S
—, effects of angiotensin converting enzyme, captopril, in essential, 213
—, effects of β-adrenoceptor antagonists on central haemodynamics in essential, 268S
—, guanethidine after twenty years: a pharmacologist's perspective, 33
—, hexamethonium, 7
—, intravenous labetalol in severe, 97S
—, intravenous labetalol in treatment of severe, 93S
—, labetalol in essential, 37S
—, malignant,—a case report, 59
—, methyldopa, 43
—, panel discussion, 135
—, prognosis of treated, 1951–1981, 71
—, propranolol and β-adrenergic receptor blocking drugs in the treatment of, 49
—, renal pathology in, and effects of treatment, 105
—, special clinics for,—the role of, detection and follow up programme, 79
—, the discovery of bretylium and bethanidine, 23
—, the introduction of ganglion blocking drugs for the treatment of, 61
—, the place of α-adrenoceptor and β-adrenoceptor blockade in treatment of, 5S
—, the problem of treatment in mild, 85
—, the Veterans trial and sequelae, 65
—, treatment of, in pregnancy with β-adrenoceptor antagonists, 375S
—, xipamide and cyclopenthiazide in essential,—comparative effects on blood pressure and plasma potassium, 859
Hypertensive vascular disease, is, reversible, 115
Hypnotics, activity and effects on performance of lormetazepam and camazepam—analogues of temazepam, 433
—, with single and multi-compartment model kinetics, 272P
Hypoglycaemia, influence of β-adrenoceptor blockers with and without ISA on hormonal responses of, and hyperglycaemia, 407S
Hypokalaemia, relative potency of potassium chloride, triamterene and spironolactone in thiazide-induced, 597P

I

ICI 118,587, haemodynamic effects of oral doses of, a β-adrenoceptor partial agonist, in healthy volunteers, 269P
Immigrants, relationship between individual dietary constituents and antipyrine metabolism in Indo-Pakistani, 481
Indomethacin, interaction between flurbiprofen and, in rheumatoid arthritis, 448
Inosine hypoxanthine, effect of pindolol on myocardial release of, and lactate during pacing-induced angina, 313S
Inotropic agent, haemodynamic effects of BM 10.188, a new orally active, in healthy volunteers, 529
Intrinsic sympathomimetic activity, and coronary blood flow, 175S
—, can, compensate for bradycardia due to β-adrenoceptor blockade, 315S
—, effect of, β-adrenoceptor blockers on circadian heart rate, 211S
—, effect of, on β-receptor responsiveness after β-adrenoceptor blockade withdrawal, 359S
—, how, modulates haemodynamic responses to β-adrenoceptor antagonists, a clue to their antihypertensive mechanism, 245S
—, influence of, during β-adrenoceptor blockade in asthmatics, 321S
—, peripheral haemodynamic effects of β-adrenoceptor blockers with, of relative β_1-selectivity at rest and during exercise, 227S
—, relationship of plasma catecholamines to blood pressure in hypertensive patients during β-adrenoceptor blockade with and without, 397S
—, vasodilating properties of β-adrenoceptor blockers with, 229S
Isoniazid, circulating hydrazine during treatment with, rifampicin in man, 599P
—, disposition, comparison of, phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control, 361
Isoprenaline, effects in man of ICI 118551 on some cardiovascular responses induced by, 586P
—, heart rate and blood pressure responses to intravenous boluses of, before and after atropine, 266P
—, interpretation of, dose response curves in presence of selective and non-selective β-adrenoceptor blockers, 585P
—, relationship of plasma concentration of oxprenolol to inhibition of, and maximum exercise tachycardia, 587P

L

Labetalol, acute and chronic hypotensive effect of, and relationship with pretreatment plasma noradrenaline levels, 87S
—, alternatives to β-blockade in therapy of hypertension with angina pectoris: role of nifedipine, or, 115S
—, blood pressure response to, in twice and three times daily administration during 24-hour period, 27S
—, comparison of, with other antihypertensive drugs, 41S
—, effects of combined α- and β-blockade by, in patients with coronary heart disease, 101S

—, elimination kinetics of, in severe renal failure, 81S
—, evaluation of, in treatment of hypertension complicating pregnancy, 127S
—, haemodynamic dose-response effects of, in coronary heart disease, 589P
—, in essential hypertension, 37S
—, in general practice: a review, 59S
—, intravenous, in severe hypertension, 97S
—, intravenous, in treatment of severe hypertension, 93S
—, proceedings of a symposium, 1S–141S
—, rapid reduction of blood pressure with acute administration of, 588P
—, rapid reduction of blood pressure with acute oral, 705
—, renal haemodynamics after chronic treatment with, and propranolol, 123S
—, response of systemic and pulmonary circulation to, at rest and during exercise, 13S
—, review of the haemodynamic effects of, in man, 19S
—, review of the long-term treatment with, 65S
—, role of, in acute myocardial infarction, 111S
—, short term effects of propranolol, atenolol and, on antipyrine kinetics in normal subjects, 817
—, steady-state pharmacokinetics in hypertensive patients, 75S
—, the nineteen-eighties, 137S
—, use of, in anaesthesia, 133S
—, use of, in Japan: results of multicentre clinical trials, 49S
Labour, a study of pethidine kinetics and analgesia in women in, following intravenous, intramuscular and epidural, 171
—, maternal kinetics and transplacental passage of pethidine during, 653
Lignocaine, effects of propranolol and pindolol on plasma clearance, in man, 223S
—, *in vitro* model for studying effects of pharmacological agents on human ciliary beat frequency: effects of lignocaine, 679
—, on the role of α_1-acid glycoprotein in, accumulation following myocardial infarction, 411
—, reduction in, clearance by cimetidine, 591P
—, saliva concentrations of, in healthy volunteers, 736
Lipids, antihypertensive drugs and blood: the Oslo study, 441S
—, effect of pindolol on serum, and, metabolizing enzymes, 445S
—, effects of pindolol and metoprolol on plasma, and lipoproteins, 435S
Lipolysis, β-adrenoceptor blockers and, 181S
Lipoproteins, effects of diuretics alone or in combination with β-adrenoceptor blockers on serum lipoproteins, 449S
Liver, assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human, 637
Liver blood flow, reduction in apparent, in man by histamine receptor blockers and inhibition of prostaglandin synthesis, 592P
Liver disease, effect of, on metabolism and elimination of phenoperidine in man, 612P
Lofexidine, antihypertensive effects of, in patients with essential hypertension, 405
Lymphocyte function, influence of β-adrenoceptor blockers on, *in vitro*, 543

M

Melphalan, h.p.l.c. method for determination of, in plasma, 605P
Menstrual cycle, influence of sex, and oral contraception on disposition of nitrazepam, 319
Methotrimeprazine, sensitive h.p.l.c. assay methods for monitoring, and dimethothiazine levels in plasma, 282P
Methoxypsoralen, difference in bioavailability between two brands of 8-, and impact on clinical response in psoriatic patients, 519
Methyldopa, 43
—, duration and effect of single daily dose, therapy, 847
—, oxprenolol, and lipids in diabetes mellitus, 219
Metoprolol, abrupt withdrawal of pindolol or, after chronic therapy, 353S
—, comparison of pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release, formulation with a new Oros® delivery system, 393
—, effect of rifampicin on, and antipyrine kinetics, 387
—, effects of pindolol and, on plasma lipids and lipoproteins, 435S
—, haemodynamic effect of, and pindolol: a comparison in hypertensive patients, 259S
Mianserin, kinetic interaction of, in epileptic patients on anticonvulsant drugs, 612P
Mianserin hydrochloride, sleep and antidepressants: studies with, and nomifensine, 603P
Midazolam, influence of age on pharmacokinetics of, 602P
Milk, clindamycin passage into human, 661
Morphine, comparative study of intramuscular buprenorphine and, in treatment of chronic pain of malignant origin, 487
Myocardial infarction, acute, selective or ISA-type β-adrenoceptor blocking drug, 299S
—, β-adrenoceptor blockade and the incidence of, during the treatment of severe hypertension, 89
—, disopyramide pharmacokinetics during recovery from, 417
—, plasma concentration of tocainide using an intravenous and oral dosage schedule for prophylaxis following, 591P
—, role of α_1-acid glycoprotein in lignocaine accumulation following, 411
—, role of labetalol in acute, 111S

N

Nadolol, comparison between atenolol and, in essential hypertension at rest and on exercise, 841
—, in thyrotoxicosis, 835
Nephrotoxicity, assessment of, 303
Nicardipine, efficacy of new calcium channel blocking agent, in chronic stable angina, 590P
Nifedipine, alternatives to β-blockade in therapy of hypertension with angina pectoris: role of, or labetalol, 115S
Nitrate, pharmacokinetics of organic, preparations, 287P
Nitrazepam, influence of sex, menstrual cycle and oral contraception on disposition of, 319
—, pharmacokinetics and psychomotor effects of, and temazepam in healthy elderly males and females, 601P

Nomifensine, pharmacokinetics of, after a single oral dose, 740
—, sleep and antidepressants; studies with mianserin hydrochloride and, 603P
Noradrenaline, acute and chronic hypotensive effect of labetalol and relationship with pretreatment plasma, levels, 87S
—, changes in blood pressure and plasma, with infusions of tyramine and, in normal subjects, 583P
—, effect of age on responses of human isolated arteries to, 237
—, elevated plasma, in response to β-adrenoceptor stimulation in man, 717

O

Opioids, and blood pressure in man, 290P
Oral contraceptive, influence of sex, menstrual cycle and, on disposition of nitrazepam, 319
—, interaction between ampicillin and, steroids in women, 280P
Oral surgery, β-adrenoceptor blockade in stress due to, 421S
Oxprenolol, comparison of effects of propranolol, pindolol, and acebutolol on atrioventricular conduction in unanaesthetised dogs, 159S
—, hydralazine interactions, 587P
—, methyldopa and lipids in diabetes mellitus, 219
—, relationship of plasma concentration of, to inhibition of isoprenaline and maximum exercise tachycardia, 587P

P

Paracetamol, antipyrine and, metabolism in obstructive jaundice, 277P
—, metabolism in heavy drinkers, 276P
Pentolinium, effect of, on plasma catecholamines in hypertensives and normal controls, 608P
Peripheral autonomic neuropathy, effects of β-adrenoceptor agonists and antagonists in patients with, 367S
Pethidine, a study of, kinetics and analgesia in women in labour following intravenous, intramuscular and epidural, 171
—, maternal kinetics and transplacental passage of, during labour, 653
Phenelzine, effects of, or amitriptyline on plasma free tryptophan during treatment of depression, 295P
Phenobarbitone, serum protein binding and free concentration of phenytoin and, in pregnancy, 547
Phenoperidine, effect of liver disease on metabolism and elimination of, in man 612P
—, plasma concentration of, and its pharmacological effects, 293P
Phenylephrine, responsiveness of sweat glands to, and carbachol in anxiety neurosis, 584P
Phenytoin, comparison of the bioavailability of two brands of, 455
—, effect of activated dimethicone and a proprietary antacid containing this agent on absorption of, 501
—, plasma protein binding of, in the aged: *in vivo* studies, 423
—, serum protein binding and free concentration of, and phenobarbitone in pregnancy, 547
Pindolol, a β-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations, 187S
—, abrupt withdrawal of, or metoprolol after chronic therapy, 353S
—, antianginal and antiarrythmic effects of, in post-infarct patients, 297S
—, cardiac dose-response relationships of oral and intravenous, 193S
—, comparison of effects of propranolol, oxprenolol and acebutolol on atrioventricular conduction in unanaesthetised dogs, 159S
—, detection of partial agonist activity of, using systolic time intervals, 268P
—, effect of, and propranolol on renal function of patients with hypertension, 241S
—, effect of intravenously administered, on skin capillary blood cell velocity in fingers, 233S
—, effect of, on exercise performance, 723
—, effect of, on myocardial blood flow, metabolism and function during rest and pacing in patients with coronary heart disease, 309S
—, effect of, on myocardial release of inosine hypoxanthine and lactate during pacing-induced angina, 313S
—, effect of, on serum lipids and lipid metabolizing enzymes, 445S
—, effects of age and smoking on pharmacokinetics of, and propranolol, 217S
—, effects of, and metoprolol on plasma lipids and lipoproteins, 435S
—, effects of propranolol and, on plasma lignocaine clearance in man, 223S
—, elevated plasma catecholamines in young hypertensive and hyperkinetic patients: effect of, 381S
—, haemodynamic effects of metoprolol and,: a comparison in hypertensive patients, 259S
—, peripheral haemodynamic effects of, 231S
—, proceedings of a symposium, the relevance of intrinsic sympathomimetic activity after 12 years of experience, 143S–450S
—, renal function during acute and long-term, treatment with hypertensive patients with normal and decreased glomerular filtration, 237S
—, the pharmacology of a partial agonist, 149S
—, therapy in pregnant hypertensive patients, 379S
Placebo, and other comparative treatments, 313
Plasma, a radioreceptor assay to study affinity of benzodiazepines and their receptor binding activity in human, 561
—, concentration of phenoperidine and its pharmacological effects, 293P
—, h.p.l.c. determination of, catecholamines in road accident casualties, 283P
—, pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in, and urine, 177
—, sensitive h.p.l.c. assay methods for monitoring methotrimeprazine and dimethothiazine levels in, 282P
Plasma binding, of drugs in patients with cancer, 263P
Platelet aggregation, methodological problems in assessment of, 265P
Potassium, comparison of prorenoate, and spironolactone

after repeated doses and steady state plasma levels of active metabolites, 187
Prazosin, addition of, to standard triple therapy in treatment of severe hypertension, 539
—, bronchodilator activity of, in patients with allergic rhinitis and asthma, 445
—, first dose phenomenon during combined treatment with a β-adrenoceptor blocker in hypertensive patients, 86S
Prednisolone, protein binding of, and vinblastine in serum of normal subjects, 595P
Pregnancy, evaluation of labetalol in treatment of hypertension complicating, 127S
—, serum protein binding and free concentration of phenytoin and phenobarbitone in, 547
—, treatment of hypertension in, with β-adrenoceptor antagonists, 375S
Prizidilol hydrochloride, assessment of β-adrenoceptor blockade in man by, 711
Procainamide acetylation, ethanol-induced increase in, in man, 203
Procaine, comparison of local anaesthetic effects of (+)-propranolol, (±)-propranolol and, on human sperm, 285P
Proceedings, of the British Pharmacological Society, University of London, Imperial College and Institute of Education, 16th–18th December, 1981, 581P–615P
—, of the British Pharmacological Society, University of Oxford, 16th–18th September, 1981, 263P–299P
263P–299P
Prochlorperazine, simple, sensitive h.p.l.c. method for assay of, in plasma, 578
Progestogen, antipyrine elimination in saliva after low-dose combined or, only oral contraceptive steroids, 229
Prolactin, bupropion fails to affect plasma, and growth hormone in normal subjects, 743
Propranolol, and β-adrenergic receptor blocking drugs in the treatment of hypertension, 49
—, comparison of effects of, pindolol, oxprenolol and acebutolol on atrioventricular conduction in unanaesthetised dogs, 159S
—, comparison of local anaesthetic affects of (+), (±), and procaine on human sperm, 285P
—, early kinetics of intravenous, 511
—, effect of acebutolol and, on hypoglycaemic action of glibenclamide, 507
—, effect of pindolol and, on renal function of patients with hypertension, 241S
—, effects of age and smoking on pharmacokinetics of pindolol and, 217S
—, effects of, and pindolol on plasma lignocaine clearance in man, 223S
—, intravenous, in patients with inflammation 577
—, renal haemodynamics after chronic treatment with labetalol and, 123S
—, short term effects of, atenolol and labetalol on antipyrine kinetics in normal subjects, 817
—, unaltered serum, binding by meal-induced variations in fatty acids, 575
—, use of buccal partitioning as a model to examine the effects of aluminium hydroxide gel on the absorption of, 399
Prostacyclin, increases filterability of normal fresh and stored human red blood cells, 298P
Prostacyclin binding, and activation of adenylate cyclase in normal and diabetic platelets, 581P
Prostacyclin synthetase, kinetics of, in umbilical artery microsomes from normal and pre-eclamptic pregnancies, 195
Prostaglandin E_2, effect of oral 16, 16-dimethyl-, on basal acid output in man, 456
Prostaglandin $F_{1\alpha}$, increased levels of 6-oxo-, in human skin following ultraviolet B irradiation, 351
Protein binding, influence of, on disopyramide clearance, 287P
—, of prednisolone and vinblastine in serum of normal subjects, 595P
—, plasma, of phenytoin in the aged: *in vivo* studies, 423
—, serum, and free concentration of phenytoin and phenobarbitone in pregnancy, 547
—, serum, of disopyramide, 288P
—, serum, of flecainide, 606P
Psoriasis, difference in bioavailability between two brands of 8-methoxypsoralen and impact on clinical response in, patients, 519

Q

Quinidine, second peak in serum levels curve after oral administration of slow-release, dosage form: effect of food, 752

R

Ranitidine, delays gastric emptying of solids in man, 252
Red blood cells, prostacyclin increases filterability of normal fresh and stored human, 298P
Renal disease, effect of, on pharmacokinetics of diethylcarbamazine in man, 829
Renal failure, elimination kinetics of labetalol in, 81S
Renal function, during acute and long-term pindolol treatment on hypertensive patients with normal and decreased glomerular filtration, 237S
—, pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired, 163
Renal insufficiency, dosage adjustment in, 145
—, prolonged converting enzyme inhibition following captopril in patients with, 754
Renal pathology, in hypertension and the effects of treatment, 105
Renin-angiotensin-aldosterone system, response of, to upright tilting and intravenous frusemide: effect of prior metoprolol and propranolol, 341
Rheumatoid arthritis, interaction between flurbiprofen and indomethacin in, 448
Rifampicin, effect of, on metoprolol and antipyrine kinetics, 387
Rowachol, how does, enhance the cholelitholytic potential of low and medium dose chenodeoxycholic acid, 278P
Rubidium chloride, effect of digoxin on *in vivo* disposition of an oral load of, 606P

S

Saliva, carbamazepine levels in children before and during multiple dosing, 647
—, concentrations of lignocaine in healthy volunteers, 736
SCH 28080, inhibitory effects of, on gastric secretion in man, 298P
β_1-Selectivity, peripheral haemodynamic effects of β-adrenoceptor blockers with ISA or relative, at rest and during exercise, 227S
Sex, influence of, menstrual cycle and oral contraception on disposition of nitrazepam, 319
Sleep, and antidepressants; studies with mianserin hydrochloride and nomifensine, 603P
Smoking, effect of age and, on pharmacokinetics of pindolol and propranolol, 217S
—, haemodynamic effects of cigarette, during β-adrenoceptor blockade, 258
Sodium fluoride, activation of human lymphocyte adenylate cyclase is reduced in old age, 871
—, lymphocyte adenylate cyclase activity and, sensitivity in relation to age, 582P
Sodium valproate, free, monitoring, 452
Sparteine, 6β-hydroxycortisol excretion in relation to polymorphic *N*-oxidation of, 737
Spironolactone, comparison of prorenoate potassium and, after repeated doses and steady state plasma levels of active metabolites, 187
—, dose-response relationships after single and repeated administrations, 596P
—, dose-response relationships in healthy subjects, 513
Stress, β-adrenoceptor blockade and psychic, in man, 391S
Sulphafurazole, plasma protein binding and half-life of, 249
Sulphasalazine, disposition and metabolism of, (salicylazosulphapyridine) in man, 523
Sulphinpyrazone, pharmacokinetics of single doses of, and its major metabolites in plasma and urine, 177
Systemic lupus erythematosus, isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic, and control, 361

T

Tachyphylaxis, after repeated dosage of decamethonium in anaesthetized man, 355
Temazepam, pharmacokinetics and psychomotor effects of nitrazepam and, in healthy elderly males and females, 601P
—, residual effects of, and flurazepam on attentional performance, 600P
Temazepam analogues, hypnotic activity and effects on performance of lormetazepam and camazepam, 433
Terbutaline, excretion into breast milk, 729
—, in breast milk, 731
Terfenadine, performance studies with the H_1-histamine antagonists, astemizole and, 199
Theophylline, dose-dependent pharmacokinetics with single daily dose slow release, in patients with chronic lung disease, 241
—, pharmacokinetics of, in night workers, 567
—, plasma, concentrations in patients with chronic obstructive airways disease after administration of new sustained release, formulation, 569
—, saliva, concentrations after single oral dose, 243
—, saliva, concentrations in single dose oral study, 296P
—, variability in bronchodilator response to, in chronic bronchitis, 610P
Thiopentone, some factors influencing induction dose of, 603P
Thyrotoxicosis, nadolol in, 835
Tinidazole, bile and serum levels of, after a single oral dose, 233
Tocainide, plasma concentrations of, using an intravenous and oral dosage schedule for prophylaxis following myocardial infarction, 591P
—, protein binding in normal volunteers and trauma patients, 872
Tolmesoxide, some effects of, in healthy volunteers, 270P
Transcortin, estimation of, concentration by measurement of plasma protein binding prednisolone and electroimmunodiffusion, 245
Triazolam, hypnotics with single and multicompartment kinetics, 272P
Triprolidine, a comparison of, and cyclizine on histamine (H_1) antagonism, subjective effects and performance in man, 441
Tyramine, changes in blood pressure and plasma noradrenaline with infusions of, and noradrenaline in normal subjects, 583P

U

UDP-glucuronyltransferase, distribution of, in different human foetal tissues, 732
Ultraviolet B, increased levels of 6-oxo-$PGF_{1\alpha}$ in human skin following, irradiation, 351
Umbilical artery, kinetics of prostacyclin synthetase in, microsomes from normal and pre-eclamptic pregnancies, 195
Upright tilting, effect of renin-angiotensin-aldosterone system to, and to intravenous frusemide: effect of prior metoprolol and propranolol, 341
Ureidopenicillin, estimation of biliary excretion of, in healthy volunteers using marker dilution technique, 795
Urinary tract, infection, 619
—, the lower, 761
—, the upper, 461
Urine, pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and, 177

V

Valproic acid, and diazepam interaction *in vivo*, 553
Ventricular function, effect of long-term cimetidine treatment on left, in haemodialysis patients with active hyperthyroidism, 693
—, influence of β-adrenoceptor blockade on left, 305S
Verapamil, bioavailability and dosage in liver disease, 240
Veterans trial, the, and sequelae, 65
Vinblastine, protein binding of prednisolone and, in serum of normal subjects, 595P

W

Wheal response, effects of adrenoceptor agonists and antagonists on a mediator induced, in human skin, 607P
Withdrawal symptoms, abrupt withdrawal of pindolol or metoprolol after chronic therapy, 353S
—, comparison of withdrawal phenomena after propranolol, metoprolol and pindolol, 345S
—, syndrome associated with withdrawal of β-adrenergic receptor blocking drugs, 337S

X

Xipamide, and cyclopenthiazide in essential hypertension—comparative effects on blood pressure and plasma potassium, 859

British Journal of Clinical Pharmacology

VOLUME 13 SUPPLEMENT 1 1982

5S GROSS, F. The place of α-adrenoceptor and β-adrenoceptor blockade in the treatment of hypertension.

13S FAGARD, ROBERT, LIJNEN, PAUL & AMERY, ANTOON. Response of the systemic and pulmonary circulation to labetalol at rest and during exercise.

19S COHN, J.N., MEHTA, J. & FRANCIS, G.S. A review of the haemodynamic effects of labetalol in man.

27S MANCIA, G., POMIDOSSI, G., PARATI, G., BERTINIERI, G., GRASSI, G., NAVONE, F., FERRARI, A., GREGORINI, L. & ZANCHETTI, A. Blood pressure response to labetalol in twice and three times daily administration during a 24-hour period.

37S BRECKENRIDGE, A., ORME, M., SERLIN, M.J. & MacIVER, M. Labetalol in essential hypertension.

41S PRICHARD, B.N.C. & RICHARDS, D.A. Comparison of labetalol with other anti-hypertensive drugs.

49S TAKEDA, T., KANEKO, Y., OMAE, T., YOSHINGA, K., MASUYAMA, Y., NUKADA, T. & SHIGIYA, R. The use of labetalol in Japan: results of multicentre clinical trials.

59S KANE, J.A. Labetalol in general practice: a review.

65S WAAL-MANNING, H.J. & SIMPSON, F.O. Review of long-term treatment with labetalol.

75S McNEIL, J.J., ANDERSON, A.E., LOUIS, W.J. & RAYMOND, K. Labetalol steady-state pharmacokinetics in hypertensive patients.

81S WOOD, A.J., FERRY, D.G. & BAILEY, R.R. Elimination kinetics of labetalol in severe renal failure.

87S AGABITI-ROSEI, E., ALICANDRI, C.L., BESCHI, M., CASTELLANO, M., FARIELLO, R., MONTINI, E., MUIESAN, M.L., ROMANELLI, G. & MUIESAN, G. The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels.

93S CUMMING, A.M.M., BROWN, J.J., LEVER, A.F. & ROBERTSON, J.I.S. Intravenous labetalol in the treatment of severe hypertension.

97S DAL PALU, C., PESSINA, A.C., SEMPLICINI, A., HLEDE, M., MORANDIN, F., PALATINI, P., SPERTI, G. & ROSSI, G.P. Intravenous labetalol in severe hypertension.

101S CONDORELLI, MARIO, BREVETTI, GREGORIO, CHIARIELLO, MASSIMO, MICELI, DOMENICO, LAVECCHIA, GUISEPPE, PAUDICE, GIAMPAOLO & VERRIENTI, SALVATORE Effects of combined α- and β-blockade by labetalol in patients with coronary artery disease.

111S TIMMIS, A.D., FOWLER, M.B., JAGGARAO, N.S.V., VINCENT, R. & CHAMBERLAIN, D.A. Role of labetalol in acute myocardial infarction.

115S OPIE, L.H., WHITE, D., LEE, J. & LUBBE, W.F. Alternatives to β-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.

123S MALINI, P.L., STROCCHI, E., NEGRONI, S., AMBROSIONI, E. & MAGNANI, B. Renal haemodynamics after chronic treatment with labetalol and propranolol.

127S MICHAEL, C.A. The evaluation of labetalol in the treatment of hypertension complicating pregnancy.

133S SCOTT, D.B. The use of labetalol in anaesthesia.

137S ROBERTSON, J.I.S. Labetalol: the Nineteen-Eighties.

VOLUME 13 SUPPLEMENT 2 1982

147S **PREFACE**

PHARMACOLOGY

149S **CLARK, B.J., MENNINGER, K. & BERTHOLET, A. Pindolol – the pharmacology of a partial agonist.**

159S KANTELIP, J.P., DUCHENE-MARULLAZ, P., DELAIGUE-FABRY, R. & ESCHALIER, A. Comparison of the effects of propranolol, pindolol, oxprenolol and acebutolol on atrioventricular conduction in unanaesthetized dogs.
167S GIUDICELLI, J.F. & LHOSTE, F. β-adrenoceptor blockade and atrio-ventricular conduction in dogs. Role of intrinsic sympathomimetic activity.
175S BERDEAUX, A. & GIUDICELLI, J.F. Intrinsic sympathomimetic activity and coronary blood flow.
181S HARMS, H.H., DE VENTE, J. & ZAAGSMA, J. β-adrenoceptor blocking agents and lipolysis.

CLINICAL PHARMACOLOGY

187S AELLIG, W.H. Pindolol – a β-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.
193S CARRUTHERS, GEORGE S. Cardiac dose-response relationships of oral and intravenous pindolol.
199S BONELLI, J. Relevance of selectivity and non-selectivity in β-adrenoceptor blocking drugs.
201S ERIKSSEN, JAN, THAULOW, ERIK, MUNDAL, REIDAR, OPSTAD, PER & NITTER-HAUGE, SIGURD. Comparison of β-adrenoceptor blockers under maximal exercise (pindolol *v* metoprolol *v* atenolol).
211S FITSCHA, P., TISO, B., MEISNER, W. & SPITZER, D. The effect of intrinsic sympathomimetic activity of β-adrenoceptor blockers on circadian heart rate.
217S HITZENBERGER, G., FITSCHA, P., BEVERIDGE, T., NÜESCH, E. & PACHA, W. Effects of age and smoking on the pharmacokinetics of pindolol and propranolol.

HAEMODYNAMIC EFFECTS

223S SVENDSEN, T., LYSBO, TANGØ, M., WALDORFF, S., STEINESS, EVA & TRAP-JENSEN, J. Effects of propranolol and pindolol on plasma lignocaine clearance in man.
227S RIECKERT, H., KATTWINKEL, W., RIECHELMANN, H., KUSS, A. & SIERAU, R. Peripheral haemodynamic effects of β-adrenoceptor blocking drugs with ISA or relative β_1-selectivity at rest and during physical exercise.
229S THULESIUS, O., GJÖRES, J.E. & BERLIN, E. Vasodilating properties of β-adrenoceptor blockers with intrinsic sympathomimetic activity.
231S OHLSSON, O. Peripheral haemodynamic effects of pindolol.
233S FAGRELL, BENGT & ÖSTERGREN, JAN. Effect of intravenously administered pindolol on skin capillary blood cell velocity in fingers.
237S ROSENFELD, JOSEPH, BONER, GEOFFREY & WAINER, EDUARDO. Renal function during acute and long term pindolol treatment in hypertensive patients with normal and decreased glomerular filtration.
241S PASTERNACK, A., PÖRSTI, P. & PÖYHÖNEN, L. Effect of pindolol and propranolol on renal function of patients with hypertension.

PERIPHERAL RESISTANCE IN HYPERTENSION

245S MAN IN 'T VELD, A.J. & SCHALEKAMP, M.A.D.H. How intrinsic sympathomimetic activity modulates the haemodynamic responses to β-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.
259S SVENSSON, ANDERS, GUDBRANDSSON, THORKELL, SIVERTSSON, RAMON & HANSSON, LENNART. Haemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients.
269S TSUKIYAMA, HISAICHIRO, OTSUKA, KEIKO & HIGUMA, KIKUHIKO. Effects of β-adrenoceptor antagonists on central haemodynamics in essential hypertension.
279S WEIL, C. & WAITE, R. Haemodynamic differences in untreated hypertension and hypertension treated with various β-adrenoceptor antagonists.

CARDIAC FUNCTION

285S HOMBACH, V., BRAUN, V., HÖPP, H.-W., GILL-SANCHEZ, D., BEHRENBECK, D.W., TAUCHERT, M. & HILGER, H.H. Electrophysiological effects of cardioselective and non-cardioselective β-adrenoceptor blockers with and without ISA at rest and during exercise.
295S SALHADIN, P., BRAN, M., DE MARNEFFE, M. & DENOLIN, H. Management of patients with chronic atrial fibrillation.
297S SAMEK, L. & ROSKAMM, H. Antianginal and antiarrhythmic effects of pindolol in post-infarct patients.

299S HEIKKILÄ, J. & NIEMINEN, M.S. Acute myocardial infarction: selective or ISA-type β-adrenoceptor blocking drug?
301S GLEICHMANN, U., FASSBENDER, D., TRIEB, G., MANNEBACH, H. & OHLMEIER, H. The influence of β-adrenoceptor antagonists with and without intrinsic sympathomimetic activity on local wall motion abnormalities in patients with coronary heart disease.
305S HAHN, B. & STRAUER, B.E. The influence of β-adrenoceptor blockade on left ventricular function.
309S KUPPER, W., HAMM, C.W. & BLEIFELD, W. The effect of pindolol on myocardial blood flow, metabolism and function during rest and pacing in patients with coronary heart disease.
313S KUGLER, G. The effect of pindolol on myocardial release of inosine, hypoxanthine and lactate during pacing-induced angina.
315S LOHMÖLLER, G. & STOCKER, K. Can ISA compensate for bradycardia due to β-adrenoceptor blockade?

BRONCHOPULMONARY FUNCTION

317S LOUIS, W.J. & McNEIL, J.J. β-adrenoceptor blocking drugs: the relevance of intrinsic sympathomimetic activity.
321S DOROW, P. Influence of intrinsic sympathomimetic activity (ISA) during β-adrenoceptor blockade in asthmatics.
325S RUFFIN, R.E., McINTYRE, E.L.M., LATIMER, K.M., WARD, H.E., CROCKETT, A.J. & ALPERS, J.H. Assessment of β-adrenoceptor antagonists in asthmatic patients.

CONSEQUENCES OF SUDDEN WITHDRAWAL

337S PRICHARD, B.N.C. & WALDEN, R.J. The syndrome associated with the withdrawal of β-adrenergic receptor blocking drugs.
345S RANGNO, ROBERT E. & LANGLOIS, SERGE. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol.
353S SZÉCSI, E., KOHLSCHÜTTER, S., SCHIESS, W. & LANG, E. Abrupt withdrawal of pindolol or metoprolol after chronic therapy.
359S WALDEN, R.J., BHATTACHARJEE, P., TOMLINSON, B., CASHIN, JEANETTE, GRAHAM, B.R. & PRICHARD, B.N.C. The effect of intrinsic sympathomimetic activity on β-receptor responsiveness after β-adrenoceptor blockade withdrawal.
365S MOLINOFF, P.B., AARONS, R.D., NIES, A.S., GERBER, J.G., WOLFE, B.B. & GOENS, M.B. Effects of pindolol and propranolol on β-adrenergic receptors on human lymphocytes.

NEW THERAPEUTIC ASPECT

367S MAN IN'T VELD, A.J., BOOMSMA, F. & SCHALEKAMP, M.A.D.H. Effects of β-adrenoceptor agonists and antagonists in patients with peripheral autonomic neuropathy.

USE IN PREGNANCY

375S DUBOIS, D., PETITCOLAS, J., TEMPERVILLE, B., KLEPPER, A. & CATHERINE, Ph. Treatment of hypertension in pregnancy with β-adrenoceptor antagonists.
379S SUKERMAN-VOLDMAN, E. Pindolol therapy in pregnant hypertensive patients.

EFFECTS ON PLASMA CATECHOLAMINES

381S DOMINIAK, P. & GROBECKER, H. Elevated plasma catecholamines in young hypertensive and hyperkinetic patients: effect of pindolol.
391S TRAP-JENSEN, JENS, CARLSEN, JAN E., HARTLING, OLE J., SVENDSEN, TAGE LYSBO, TANGØ, MOGENS & CHRISTENSEN, NIELS JUEL. β-adrenoceptor blockade and psychic stress in man. A comparison of the acute effects of labetalol, metoprolol, pindolol and propranolol on plasma levels of adrenaline and noradrenaline.
397S KIRSTEN, R., HEINTZ, B., BÖHMER, D., NELSON, K., ROTH, S. & WELZEL, D. Relationship of plasma catecholamines to blood pressure in hypertensive patients during β-adrenoceptor blockade with and without intrinsic sympathomimetic activity.

METABOLIC EFFECTS

407S SCHLÜTER, K.J., AELLIG, W.H., PETERSEN, K.-G., RIEBAND, H.-CH., WEHRLI, A. & KERP, L. The influence of β-adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia.

419S RAPTIS, S. Effects of cardioselective and non-selective β-adrenoceptor blockade on glycogenolysis, lipolysis and growth hormone secretion.
421S BRISSE, B., TETSCH, P., JACOBS, W. & BENDER, F. β-adrenoceptor blockade in stress due to oral surgery.
429S DOROW, P. Effects of β-adrenoceptor blockade on carbohydrate metabolism during exercise – comparison of pindolol and metoprolol.

EFFECTS ON PLASMA UPOPROTEINS

431S MIETTINEN, T.A., VANHANEN, H., HUTTUNEN, J.K., NAUKKARINEN, V., MATTILA, S., STRANDBERG, T. & KUMLIN, T. HDL cholesterol and β-adrenoceptor blocking agents in a 5 year multifactorial primary prevention trial.
435S PASOTTI, C., CAPRA, A., FIORELLA, G., VIBELLI, C. & CHIERICHETTI, S.M. Effects of pindolol and metoprolol on plasma lipids and lipoproteins.
441S LEREN, P., EIDE, I., FOSS, O.P., HELGELAND, A., HJERMANN, I., HOLME, I., KJELDSEN, S.E. & LUND-LARSEN, P.G. Antihypertensive drugs and blood lipids: the Oslo Study.
445S LEHTONEN, A., HIETANEN, E., MARNIEMI, J., PELTONEN, P. & NISKANEN, J. Effect of pindolol on serum lipids and lipid metabolizing enzymes.
449S WEIDMANN, P., SCHIFFL, H., BOEHRINGER, K., MEIER, A., MORDASINI, R. & RIESEN, W. Effects of diuretics alone or in combination with β-adrenoceptor blockers on serum lipoproteins.

VOLUME 13 NUMBER 1 JANUARY 1982

3 Introduction.
4 Editorial note.
5 Sir John McMichael.
7 PATON, W.D.M. Hexamethonium.
15 BEYER, KARL H. Chlorothiazide.
25 GREEN, A.F. The discovery of bretylium and bethanidine.
35 MAXWELL, ROBERT A. Guanethidine after twenty years: a pharmacologist's perspective.
45 SJOERDSMA, ALBERT. Methyldopa.
51 PRICHARD, B.N.C. Propranolol and β-adrenergic receptor blocking drugs in the treatment of hypertension.
61 BRODIE, MARTIN J. Malignant hypertension—a case report.
63 DOYLE, A.E. The introduction of ganglion blocking drugs for the treatment of hypertension.
67 FREIS, EDWARD D. The Veterans trial and sequelae.
73 BULPITT, C.J. Prognosis of treated hypertension 1951–1981.
81 KASS, EDWARD H. Special clinics for hypertension—the role of the Hypertension Detection and Follow-up Programme.
87 PEART, W.S. The problem of treatment in mild hypertension.
91 STEWART, I.McD.G. β-adrenoceptor blockade and the incidence of myocardial infarction during treatment of severe hypertension.
95 KORNER, P.I. Circulatory regulation in hypertension.
107 KINCAID-SMITH, PRISCILLA. Renal pathology in hypertension and the effects of treatment.
117 BEILIN, L.J. Is hypertensive vascular disease reversible?
127 DOLLERY, C.T. A clinician looks at the future.
133 GROSS, F. Can we develop new drugs for hypertension?
137 Panel Discussion.

VOLUME 13 NUMBER 2 FEBRUARY 1982

METHODS IN CLINICAL PHARMACOLOGY

145 MAWER, G.E. Dosage adjustment in renal insufficiency.
155 CHAPUT DE SAINTONGE, M. & VERE, D.W. Methods in clinical pharmacology: clinical trials series.
157 ROSE, G. Bias.

PAPERS

163 LARSSON, R., ERLANSON, P., BODEMAR, G., WALAN, A., BERTLER, A., FRANSSON, L. & NORLANDER, B. The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.

171 HUSEMEYER, R.P., CUMMINGS, A.J., ROSANKIEWICZ, J.R. & DAVENPORT, H.T. A study of pethidine kinetics and analgesia in women in labour following intravenous, intramuscular and epidural administration.

177 BRADBROOK, I.D., JOHN, V.A., MORRISON, P.J., ROGERS, H.J. & SPECTOR, R.G. Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.

187 McINNES, G.T., SHELTON, J.R., HARRISON, I.R., PERKINS, R.M. & PALMER, R.F. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.

195 DOWNING, IAN, SHEPHERD, GILLIAN L. & LEWIS, PETER J. Kinetics of prostacyclin synthetase in umbilical artery microsomes from normal and pre-eclamptic pregnancies.

199 NICHOLSON, A.N. & STONE, BARBARA M. Performance studies with the H_1-histamine receptor antagonists, astemizole and terfenadine.

203 OLSEN, HARALD & MØRLAND, JØRG. Ethanol-induced increase in procainamide acetylation in man.

209 MITENKO, PAUL A., McKENZIE, JOHN K. & BROSSARD, JEAN-JACQUES. Antihypertensive action of acebutolol (Sectral) when used concomitantly with hydrochlorothiazide.

213 CAMPBELL, B.C., SHEPHERD, A.N. & REID, J. L. Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.

219 BENFIELD, G.F.A. & HUNTER, K.R. Oxprenolol, methyldopa and lipids in diabetes mellitus.

223 BUSTO, U., NARANJO, C.A. & SELLERS, E.M. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions.

229 CHAMBERS, D.M., JEFFERSON, G.C., CHAMBERS, MARGARET & LOUDON, NANCY B. Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids.

LETTERS TO THE EDITORS

233 HUNT, P.S., DAVIDSON, A.J.L., ALDEN, J. & CHENG, S. Bile and serum levels of tinidazole after a single oral dose.

235 RUBIN, PETER C., SCOTT, PETER J.W., McLEAN, KATHLEEN, PEARSON, ANDREW, ROSS, DOUGLAS & REID, JOHN L. Atenolol disposition in young and elderly subjects.

237 SCOTT, PETER J.W. & REID, JOHN L. The effect of age on the responses of human isolated arteries to noradrenaline.

239 TFELT-HANSEN, P., PAALZOW, L. & IBRAHEEM, J.J. Bioavailability of sublingual ergotamine.

240 WOODCOCK, BARRY G. & RIETBROCK, NORBERT. Verapamil bioavailability and dosage in liver disease.

241 BUTCHER, M.A., FRAZER, L.A., REDDEL, H.K. & MARLIN, G.E. Dose-dependent pharmacokinetics with single daily dose slow release theophylline in patients with chronic lung disease.

243 CULIG, J., JOHNSTON, A. & TURNER, P. Saliva theophylline concentrations after a single oral dose.

245 FREY, B.M. & FREY, F.J. Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion.

249 ARUNKUMAR SHASTRI, R. Plasma protein binding and half-life of sulphisoxazole (sulphafurazole).

250 VALETTE, HÉRIC, APOIL, EDITHE & HILPERT, FRANÇOIS. Effects of heating on haemodynamic action of glyceryl trinitrate.

252 SCARPIGNATO, CARMELO, BERTACCINI, GIULIO, ZIMBARO, GIOVANNI & VITULO, FELICE. Ranitidine delays gastric emptying of solids in man.

253 GRIFFIN, J.P. & STEWART, A.G. Six months experience of new procedures affecting the conduct of clinical trials in the United Kingdom.

255 CAMPBELL, B.C. Are propranolol and nifedipine synergistic in angina pectoris?
256 TWEDDEL, A.C., BEATTIE, J.M., MURRAY, R.G. & HUTTON, I. Are propranolol and nifedipine synergistic in angina pectoris? A reply.
256 SILKE, B. Relationship between plasma β-adrenoceptor blocker concentration and pharmacodynamic activity.
257 JENNINGS, G.L., BOBIK, A. & KORNER, P.I. Influence of intrinsic sympathomimetic activity of β-adrenoceptor blockers on the heart rate and blood pressure responses to graded exercise.
258 FREESTONE, S. & RAMSAY, L.E. Haemodynamic effects of cigarette smoking during β-adrenoceptor blockade.
259 HOUBEN, H., THIEN, TH. & VAN 'T LAAR, A. Haemodynamic effects of cigarette smoking during β-adrenoceptor blockade—a reply.
260 THOMIS, J.A., SOEP, H.H., HALLYNCK, T., BOELAERT, J., DANEELS, R. & DETTLI, L. Creatinine clearance, different methods of determination.
261 KAMPMANN, J. & MØLHOLM-HANSEN, J.E. Creatinine clearance, different methods of determination; a reply.
263P PROCEEDINGS OF THE BRITISH PHARMACOLOGICAL SOCIETY. University of Oxford, 16th–18th September, 1981.

VOLUME 13 NUMBER 3 MARCH 1982

METHODS IN CLINICAL PHARMACOLOGY

303 PRESCOTT, L.F. Assessment of nephrotoxicity.
313 JOYCE, C.R.B. Placebos and other comparative treatments.

PAPERS

319 JOCHEMSEN, R., VAN DER GRAAFF, M., BOEIJINGA, J.K. & BREIMER, D.D. Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam.
325 BACK, D.J., BRECKENRIDGE, A.M., MacIVER, M., ORME, M., PURBA, H.S., ROWE, P.H. & TAYLOR, I. The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans.
331 McINNES, G.T., SHELTON, J.R., RAMSAY, L.E., HARRISON, I.R., ASBURY, M.J., CLARKE, J.M., PERKINS, R.M. & VENNING, G.R. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience.
341 SONKODI, S., AGABITI-ROSEI, E., FRASER, R., LECKIE, B.J., MORTON, J.J., CUMMING, A.M.M., SOOD, V.P. & ROBERTSON, J.I.S. Response of the renin-angiotensin-aldosterone system to upright tilting and to intravenous frusemide: effect of prior metoprolol and propranolol.
351 BLACK, A.K., HENSBY, C.N. & GREAVES, M.W. Increased levels of 6-oxo-$PGF_{1\alpha}$ in human skin following ultraviolet B irradiation.
355 HUGHES, R., AL-AZAWI, S. & PAYNE, J.P. Tachyphylaxis after repeated dosage of decamethonium in anaesthetized man.
361 HORAI, YUKIO, ISHIZAKI, TAKASHI, SASAKI, TOMIO, KOYA, GYOICHI, MATSUYAMA, KENJI & IGUCHI, SADAO. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.
375 LEE, EDMUND J.D. & LEE, LIONEL K.H. A simple pharmacokinetic method for separating the three acetylation phenotypes; a preliminary report.
379 DANHOF, M., VERBEEK, R.M.A., VAN BOXTEL, C.J., BOEIJINGA, J.K. & BREIMER, D.D. Differential effects of enzyme induction on antipyrine metabolite formation.
387 BENNETT, P.N., JOHN, V.A. & WHITMARSH, V.B. Effect of rifampicin on metoprolol and antipyrine kinetics.
393 KENDALL, MARTIN J., JACK, DAVID B., WOODS, KENT L., LAUGHER, STEVEN J., QUARTERMAN, CHARMAINE P. & JOHN, VIVIAN A. Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros ® delivery system.

399 McELNAY, J.C. & TEMPLE, D.J. The use of buccal partitioning as a model to examine the effects of aluminium hydroxide gel on the absorption of propranolol.
405 FAGAN, TIMOTHY C., BLOOMFIELD, SAUL S., COWART, T. DOUGLAS, CORNS-HURWITZ, REBECCA H., LIPICKY, RAYMOND, J., CONRADI, EDWARD C., HSU, CHUNG-YI, GROSSMAN, WILLIAM J., HARMON, GERALD E., DEGENHART, WILLIAM J., SINKFIELD, ALFREDA W. & GAFFNEY, THOMAS E. Antihypertensive effects of lofexidine in patients with essential hypertension.
411 BARCHOWSKY, A., SHAND, D.G., STARGEL, W.W., WAGNER, G.S. & ROUTLEDGE, P.A. On the role of α_1-acid glycoprotein in lignocaine accumulation following myocardial infarction.
417 BRYSON, SCOTT M., CAIRNS, CHRISTOPHER J. & WHITING, BRIAN. Disopyramide pharmacokinetics during recovery from myocardial infarction.
423 PATTERSON, M., HEAZELWOOD, R., SMITHURST, B. & EADIE, M.J. Plasma protein binding of phenytoin in the aged: *in vivo* studies.
427 DHILLON, SORAYA, OXLEY, JOLYON & RICHENS, ALAN. Bioavailability of diazepam after intravenous oral and rectal administration in adult epileptic patients.
433 NICHOLSON, A.N. & STONE, BARBARA M. Hypnotic activity and effects on performance of lormetazepam and camazepam—analogues of temazepam.
441 HAMILTON, MARGARET, BUSH, MAUREEN, BYE, CAROLE & PECK, A.W. A comparison of triprolidine and cyclizine on histamine (H_1) antagonism, subjective effects and performance tests in man.

LETTERS TO THE EDITORS

445 MARLIN, G.E., THOMPSON, P.J., REDELL, H.K., CHOW, C.M. & CHENG, S. Bronchodilator activity of prazosin in patients with allergic rhinitis and asthma.
448 RUDGE, S.R., LLOYD-JONES, J.K. & HIND, I.D. Interaction between flurbiprofen and indomethacin in rheumatoid arthritis.
451 ADELUSI, S.A. & SALAKO, L.A. Protein binding of chloroquine in the presence of aspirin.
452 ROMAN, E. JAGER, PONNIAH P., LAMBERT, J. BAIRD & BUCHANAN, N. Free sodium valproate monitoring.
455 GIBBERD, F.B., SPENCER, KATHLEEN M., WEBLEY, M. & BERRY, D. A comparison of the bioavailability of two brands of phenytoin.
456 DAMMANN, H.G., MÜLLER, P. & SIMON, B. Effect of oral 16, 16-dimethylprostaglandin E_2 on basal acid output in man.

VOLUME 13 NUMBER 4 APRIL 1982

METHODS IN CLINICAL PHARMACOLOGY

461 LONGRIGG, J.N. The upper urinary tract.
469 CLAYTON, D.G. Ethically optimised designs.

PAPERS

481 MUCKLOW, J.C., CARAHER, MARIE T., HENDERSON, D.B., CHAPMAN, P.H., ROBERTS, D.F. & RAWLINS, M.D. The relationship between individual dietary constituents and antipyrine metabolism in Indo-Pakistani immigrants to Britain.
487 KJAER, MOGENS, HENRIKSEN, HANS & KNUDSEN, JULIE A comparative study of intramuscular buprenorphine and morphine in the treatment of chronic pain of malignant origin.
493 TSUJIMOTO, GOZOH, SASAKI, TOMIO, ISHIZAKI, TAKASHI, SUGANAMA, TOSHIYUKI & HIRAYAMA, HIROKI Re-examination of digoxin dosage regimen: comparison of the proposed nomograms or formulae in elderly patients.
501 McELNAY, J.C., UPRICHARD, G. & COLLIER, P.S. The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin.
507 ZAMAN, R., KENDALL, M.J. & BIGGS, P.I. The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.

513 McINNES, GORDON T., PERKINS, RICHARD M., SHELTON, JOHN R. & HARRISON, IAN R. Spironolactone dose-response relationships in healthy subjects.
519 HERFST, MARJA J. & DE WOLFF, FREDERIK A. Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients.
523 AZAD KHAN, A.K., TRUELOVE, S.C. & ARONSON, J.K. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
529 WHITING, BRIAN, KELMAN, ANDREW W., SUMNER, DAVID J., HILLIS, W. STEWART & LEDERMANN, HELLMUTH Haemodynamic effects of BM 10. 188, a new orally active inotropic agent, in healthy volunteers.
533 THIBONNIER, M., FLABEAU, C., THOUVENIN, M., ROUX, A., FLOUVAT, B., PASQUIER, P. & MENARD, J. Antihypertensive effect of diacetolol in essential hypertension.
539 HEAGERTY, A.M., RUSSELL, G.I., BING, R.F., THURSTON, H. & SWALES, J.D. The addition of prazosin to standard triple therapy in the treatment of severe hypertension.
543 HALLENGREN, BENGT, FORSGREN, ARNE & MELANDER, ARNE Influence of β-adrenoceptor blocking agents on lymphocyte function *in vitro*.
547 CHEN, SHUN-SHENG, PERUCCA, EMILIO, LEE, JAU-NAN & RICHENS, ALAN Serum protein binding and free concentration of phenytoin and phenobarbitone in pregnancy.
553 DHILLON, SORAYA & RICHENS, ALAN Valproic acid and diazepam interaction *in vivo*.
561 DOROW, RAINER G., SEIDLER, JÖRG & SCHNEIDER, HERBERT H. A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites.

LETTERS TO THE EDITORS

567 DECOURT, S., FODOR, F., FLOUVAT, B., PRADALIER, A. & DRY, J. Pharmacokinetics of theophylline in night-workers.
569 TAYLOR, D.R., KINNEY, C.D. & McDEVITT, D.G. Plasma theophylline concentrations in patients with chronic obstructive airways disease after administration of a new sustained release theophylline formulation.
511 FAGAN, T.C., WALLE, T., WALLE, U.K., CONRADI, E.C., HARMON, G. & GAFFNEY, T.E. Early kinetics of intravenous propranolol.
575 NARANJO, C.A., SELLERS, E.M. & KHOUW, V. Unaltered serum propranolol binding by meat-induced variations in fatty acids.
577 WALLER, D.G., SMITH, C.L., RENWICK, A.G. & GEORGE, C.F. Intravenous propranolol in patients with inflammation.
578 SANKEY, M.G., HOLT, JACQUELYN E. & KAYE, C.M. A simple and sensitive h.p.l.c. method for the assay of prochlorperazine in plasma.
581P PROCEEDINGS OF THE BRITISH PHARMACOLOGICAL SOCIETY. University of London, 16th–18th December, 1981.

VOLUME 13 NUMBER 5 MAY 1982

METHODS IN CLINICAL PHARMACOLOGY

619 GREENWOOD, D. & SLACK, R. Urinary tract infection.
631 ELWOOD, P.C. Randomised controlled trials: sampling.

PAPERS

637 KAHN, G.C., BOOBIS, A.R., MURRAY, S., BRODIE, M.J. & DAVIES, D.S. Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.
647 MORELAND, T.A., PRIESTMAN, D.A. & RYLANCE, G.W. Saliva carbamazepine levels in children before and during multiple dosing.
653 TOMSON, G., GARLE, RES. ING. M., THALME, B., NISELL, H., NYLUND, L. & RANE, A. Maternal kinetics and transplacental passage of pethidine during labour.
661 STEEN, BENGT & RANE, ANDERS Clindamycin passage into human milk.

665 BULLINGHAM, R.E.S., McQUAY, H.J., PORTER, E.J.B., ALLEN, M.C. & MOORE, R.A. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis.
675 BATEMAN, D.N., GOOPTU, D. & WHITTINGHAM, T.A. The effects of domperidone on gastric emptying of liquid in man.
679 RUTLAND, JONATHAN, GRIFFIN, WAYNE & COLE, PETER J. An *in vitro* model for studying the effects of pharmacological agents on human ciliary beat frequency: effects of lignocaine.
685 JOSEFSSON, K., BERGAN, T. & MAGNI, L. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base.
693 LAI, K.N., FASSETT, R.G. & MATHEW, T.H. Effect of long-term cimetidine treatment on left ventricular function in haemodialysis patients with active hyperparathyroidism.
699 ELLIOTT, H.L., MEREDITH, P.A., SUMNER, D.J., McLEAN, K. & REID, J.L. A pharmacodynamic and pharmacokinetic assessment of a new α-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.
705 DAVIES, A.B., BALA SUBRAMANIAN, V., GOULD, B. & RAFTERY, E.B. Rapid reduction of blood pressure with acute oral labetalol.
711 PITCHER, D.W., CURRY, P.V.L. & TROUNCE, J.R. An assessment of β-adrenoceptor blockade in man by prizidilol hydrochloride.
717 VINCENT, H.H., MAN IN't VELD, A.J., BOOMSMA, F., WENTING, G.J. & SCHALEKAMP, M.A.D.H. Elevated plasma noradrenaline in response to β-adrenoceptor stimulation in man.
723 DHATARIYA, R.C. & BLOWERS, A.J. The effect of the β-adrenoceptor antagonist pindolol on exercise performance.

LETTERS TO THE EDITORS

729 LÖNNERHOLM, GUDMAR & LINDSTRÖM, BJÖRN. Terbutaline excretion into breast milk.
731 BORÉUS, L.O., de CHÂTEAU, P., LUNDBERG, C. & NYBERG, L. Terbutaline in breast milk.
732 PACIFICI, GIAN MARIA & RANE, ANDERS Distribution of UDP-glucuronyltransferase in different human foetal tissues.
736 KANTO, J., SELLMAN, R. & LAURIKANIEN, E. Saliva concentrations of lignocaine in healthy volunteers.
737 PARK, B.K., EICHELBAUM, M. & OHNHAUS, E.E. 6 β-Hydroxycortisol excretion in relation to polymorphic *N*-oxidation of sparteine.
740 McINTYRE, IAIN, NORMAN, TREVOR, P., BURROWS, GRAHAM D. & MAGUIRE, KAY P. Pharmacokinetics of nomifensine after a single oral dose.
743 WHITEMAN, P.D., PECK, A.W., FOWLE, A.S.E. & SMITH, P. Bupropion fails to affect plasma prolactin and growth hormone in normal subjects.
745 DESAI, N.K., KARBHARI, K., PAUL, T., KSHIRSAGAR, N.A. & SHETH, U.K. Prolongation of antipyrine half-life after correction of severe anaemia due to hook-worm infestation.
747 VANDENBURG, M.J., WRIGHT, PATRICIA, HOLMES, J., ROGERS, H.J. & AHMAD, R.A. The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.
750 DAYER, P., KUBLI A., KUPFER, A., COURVOISIER, F., BALANT, L. & FABRE, J. Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.
752 SPENARD, J., SIROIS, G. & GAGNON, M.A. The second peak in the serum levels curve after oral administration of a slow-release quinidine dosage form: effect of food.
755 CAMPBELL, B.C., SHEPHERD, A.N., ELLIOTT, H.L., McLEAN, C. & REID, J.L. Prolonged converting enzyme inhibition following captopril in patients with renal insufficiency.

VOLUME 13 NUMBER 6 JUNE 1982

METHODS IN CLINICAL PHARMACOLOGY

761 ROBINSON, JEAN M. The lower urinary tract.
775 CHAPUT DE SAINTONGE, D.M. & VERE, D.W. Measurement in clinical trials.

PAPERS

785 LITTLE, P.J., JENNINGS, G.L., SKEWS, H. & BOBIK, A. Bioavailability of dihydroergotamine in man.

791 WANG, C., LAI, C.L., LAM, K.C. & YEUNG, K.K. Effect of cimetidine on gonadal function in man.

795 GUNDERT-REMY, U., FROHNAPFEL, F., JOURDAN, W., WEBER, E. & STIEHL, A. Estimation of biliary excretion of ureidopenicillins in healthy volunteers using marker dilution technique.

803 HURLOW, R.A., AUCKLAND, A., HARDMAN, J. & WHITTINGTON, J.R. Studies of the haemodynamic effects of creatine phosphate in man.

807 SEYMOUR, R.A. & RAWLINS, M.D. Efficacy and pharmacokinetics of aspirin in postoperative dental pain.

811 FORSYTH, J. STEWART, MORELAND, TERENCE A. & RYLANCE, GEORGE W. The effect of fever on antipyrine metabolism in children.

817 DANESHMEND, T.K. & ROBERTS, C.J.C. The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects.

821 HARRON, D.W.G., ARNDTS, D. & SHANKS, R.G. Alinidine pharmacokinetics following acute and chronic dosing.

829 ADJEPON-YAMOAH, K.K., EDWARDS, G., BRECKENRIDGE, A.M., ORME, M.L'E & WARD, S.A. The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man.

835 PEDEN, N.R., ISLES, T.E., STEVENSON, I.H. & CROOKS, J. Nadolol in thyrotoxicosis.

841 WILCOX, R.G. & HAMPTON, J.R. Comparison between atenolol and nadolol in essential hypertension at work and on exercise.

847 WRIGHT, J.M., OROZCO-GONZALEZ, M., POLAK, G. & DOLLERY, C.T. Duration of effect of single daily dose methyldopa therapy.

855 ATKINSON, A.B., CUMMING, A.M.M., BROWN, J.J., FRASER, R., LECKIE, B., LEVER, A.F., MORTON, J.J. & ROBERTSON, J.I.S. Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure.

859 MacGREGOR, GRAHAM A., BANKS, RICHARD A., MARKANDU, NIRMALA D. & ROULSTON, JOE Xipamide and cyclopenthiazide in essential hypertension—comparative effects on blood pressure and plasma potassium.

865 SEIDEMAN, PETER, GRAHNÉN, ANDERS, HAGLUND, KJELL, LUNDSTRÖM, BJÖRN & VON BAHR, CHRISTER Prazosin first dose phenomenon during combined treatment with a β-adrenoceptor blocker in hypertensive patients.

LETTERS TO THE EDITORS

871 DOYLE, V.M., O'MALLEY, K. & KELLY, J.G. Sodium fluoride activation of human lymphocyte adenylate cyclase is reduced in old age.

872 ELVIN, A.T., AXELSON, J.E. & LALKA, D. Tocainide protein binding in normal volunteers and trauma patients.